- en: <!--yml
  prefs: []
  type: TYPE_NORMAL
- en: 'category: 未分类'
  prefs: []
  type: TYPE_NORMAL
- en: 'date: 2024-05-27 13:22:52'
  prefs: []
  type: TYPE_NORMAL
- en: -->
  prefs: []
  type: TYPE_NORMAL
- en: 'Magnesium Depletion Score and Metabolic Syndrome in US Adults: Analysis of
    NHANES 2003 to 2018 | The Journal of Clinical Endocrinology & Metabolism | Oxford
    Academic'
  prefs:
  - PREF_H1
  type: TYPE_NORMAL
- en: 来源：[https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae075/7608307](https://academic.oup.com/jcem/advance-article/doi/10.1210/clinem/dgae075/7608307)
  prefs:
  - PREF_BQ
  type: TYPE_NORMAL
- en: Abstract
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
- en: Context
  prefs: []
  type: TYPE_NORMAL
- en: The association between magnesium status and metabolic syndrome (MetS) remains
    unclear.
  prefs: []
  type: TYPE_NORMAL
- en: Objective
  prefs: []
  type: TYPE_NORMAL
- en: This study aimed to examine the relationship between kidney reabsorption-related
    magnesium depletion score (MDS) and MetS among US adults.
  prefs: []
  type: TYPE_NORMAL
- en: Methods
  prefs: []
  type: TYPE_NORMAL
- en: We analyzed data from 15 565 adults participating in the National Health and
    Nutrition Examination Survey (NHANES) 2003 to 2018\. MetS was defined according
    to the National Cholesterol Education Program's Adult Treatment Panel III report.
    The MDS is a scoring system developed to predict the status of magnesium deficiency
    that fully considers the pathophysiological factors influencing the kidneys' reabsorption
    capability. Weighted univariate and multivariable logistic regression were used
    to assess the association between MDS and MetS. Restricted cubic spline (RCS)
    analysis was conducted to characterize dose-response relationships. Stratified
    analyses by sociodemographic and lifestyle factors were also performed.
  prefs: []
  type: TYPE_NORMAL
- en: Results
  prefs: []
  type: TYPE_NORMAL
- en: In both univariate and multivariable analyses, higher MDS was significantly
    associated with increased odds of MetS. Each unit increase in MDS was associated
    with approximately a 30% higher risk for MetS, even after adjusting for confounding
    factors (odds ratio 1.31; 95% CI, 1.17-1.45). RCS graphs depicted a linear dose-response
    relationship across the MDS range. This positive correlation remained consistent
    across various population subgroups and exhibited no significant interaction by
    age, sex, race, adiposity, smoking status, or alcohol consumption.
  prefs: []
  type: TYPE_NORMAL
- en: Conclusion
  prefs: []
  type: TYPE_NORMAL
- en: Higher urinary magnesium loss as quantified by MDS may be an independent linear
    risk factor for MetS in US adults, irrespective of sociodemographic and behavioral
    factors. Optimizing magnesium nutritional status could potentially confer benefits
    to patients with MetS.
  prefs: []
  type: TYPE_NORMAL
- en: 'Metabolic syndrome (MetS) is a common metabolic disorder caused by the increasing
    prevalence of obesity, and currently, this disorder is defined in various ways.
    In the 1980s, Reaven clustered the risk factors for diabetes and cardiovascular
    diseases together and called it “syndrome X,” which includes insulin resistance,
    hypertension, hyperglycemia, low high-density lipoprotein cholesterol (HDL-c),
    and high triglycerides (TGs) (1). Insulin resistance is defined clinically as
    the inability of a known quantity of exogenous or endogenous insulin to increase
    glucose uptake and utilization in an individual as much as it does in a normal
    population (2). In 1992, after central obesity was added as a core component of
    the definition and entity, it was renamed insulin resistance syndrome (IRS) (3).
    In 1998, The World Health Organization uniformly named it “metabolic syndrome”
    (MetS) and proposed that insulin resistance is the core of the pathophysiology
    of MetS (4). In the following years, the definitions of MetS revised according
    to the racial conditions of other countries also appeared, among which the more
    influential ones include the definition of the National Cholesterol Education
    Program Adult Treatment Panel III Criteria (NCEP-ATP III) (5) and the definition
    of the International Diabetes Federation. According to the NCEP ATP III definition,
    MetS is diagnosed as the presence of at least 3 of the following 5 characteristics:
    high waist circumference, high blood pressure, elevated blood sugar level, increased
    TGs, and low HDL-c (5). MetS is important because of its association with an increasing
    prevalence of diabetes and a higher risk of cardiovascular events such as heart
    disease and stroke, which have become a major public health challenge.'
  prefs: []
  type: TYPE_NORMAL
- en: Magnesium is a vital mineral in the human body, serving as an essential cofactor
    for hundreds of enzymatic reactions. These include energy metabolism, protein
    and nucleic acid synthesis, and the secretion and action of insulin (6, 7). It
    plays a crucial role in maintaining normal nerve and muscle function, supporting
    a healthy immune system, and ensuring a steady heartbeat. Despite its importance,
    magnesium deficiency is a widespread and often overlooked public health issue.
    More than half of the US population fails to meet the recommended dietary allowance
    for magnesium intake, leading to a high estimated prevalence (∼15%) of magnesium
    deficiency (8). Studies have found that hypomagnesemia is associated with elevated
    risk and adverse prognosis in patients with diabetes, stroke, and coronary artery
    disease. Increasing magnesium intake can reduce the risk of diabetes, stroke and
    hypertension (9, 10).
  prefs: []
  type: TYPE_NORMAL
- en: Although serum magnesium is frequently used in clinical settings to assess magnesium
    deficiency (11), it may not accurately reflect the body's overall magnesium status.
    This is largely due to the kidneys’ role in absorbing more than 80% of plasma
    magnesium, a process vital for maintaining magnesium homeostasis. In light of
    this, Fan et al (12) developed the magnesium depletion score (MDS), a composite
    score that aggregates 4 established risk factors and also takes into account the
    pathophysiological factors influencing the kidneys’ reabsorption capability. A
    higher MDS indicates a more severe state of magnesium deficiency. However, to
    our knowledge, the association between the MDS and MetS has not been studied.
    It may therefore be helpful to further explore the relationship between MDS and
    MetS to develop future prevention or treatment methods for this disease. We investigated
    the association between MDS and MetS by examining 80 312 participants from the
    NHANES from 2003 to 2018.
  prefs: []
  type: TYPE_NORMAL
- en: Materials and Methods
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
- en: Study Population and Design
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
- en: Data for this study were obtained from the National Health and Nutrition Examination
    Survey website ([https://www.cdc.gov/nchs/nhanes/index.htm](https://www.cdc.gov/nchs/nhanes/index.htm)).
    In this study, 9 cycles of NHANES data (2003-2018) were collected by the Centers
    for Disease Control and Prevention. NHANES is a multistage, stratified, large,
    nationally representative study of the US population that provides detailed information
    about the study design, interviews, demographics, etc (13-15). Among the sample
    of 80 312 adults, those who did not provide MDS information or other variables
    were excluded (Fig. 1). Protocol approval was granted by the National Center for
    Health Statistics’ ethical review board, and informed consent forms were signed
    by participants.
  prefs: []
  type: TYPE_NORMAL
- en: Figure 1.
  prefs: []
  type: TYPE_NORMAL
- en: Flowchart of participant selection from National Health and Nutrition Examination
    Survey 2003 to 2018.
  prefs: []
  type: TYPE_NORMAL
- en: Calculation of the Magnesium Depletion Score
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
- en: 'The MDS was calculated to evaluate total-body magnesium status. The MDS was
    calculated as the sum of the following 4 scores: (1) current use of diuretics
    was scored 1 point; (2) current use of proton pump inhibitor (PPI) was scored
    1 point; (3) an estimated glomerular filtration rate (eGFR) between 60 mL/min/1.73 m²
    and 90 mL/min/1.73 m² was scored 1 point, while an eGFR less than 60 mL/min/1.73 m²
    was scored 2 points; and (4) heavy drinking (>1 drink/d for women and >2 drinks/d
    for men) was scored 1 point (12). The eGFR was calculated using the Chronic Kidney
    Disease Epidemiology Collaboration formula (16). According to the Food Patterns
    Equivalents Database, alcoholic drinks include all types of beers, wines, distilled
    spirits (such as brandy, gin, rum, vodka, and whiskey), cordials, and liqueurs.
    One drink was defined as the amount of alcoholic beverage containing 0.6 fluid
    ounces or 14 g of ethanol. MDS was categorized into 6 groups: MDS = 0, MDS = 1,
    MDS = 2, MDS = 3, MDS = 4, and MDS = 5.'
  prefs: []
  type: TYPE_NORMAL
- en: Diagnosis of Metabolic Syndrome
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
- en: 'MetS was defined according to the NCEP-ATP III report (5). Participants were
    diagnosed with MetS if they met at least 3 of the following 5 criteria: (1) central
    obesity: waist circumference greater than or equal to 102 cm in men, or greater
    than or equal to 88 cm in women; (2) hypertriglyceridemia: serum TGs greater than
    or equal to 150 mg/dL; (3) low HDL-c: serum HDL-c less than 40 mg/dL in men and
    less than 50 mg/dL in women; (4) hypertension: systolic blood pressure (SBP) greater
    than or equal to 130 mm Hg, or diastolic blood pressure (DBP) greater than or
    equal to 85 mm Hg, or receiving antihypertensive treatment; (5) hyperglycemia:
    fasting glucose greater than or equal to 100 mg/dL, or receiving antihyperglycemic
    treatments. Data on waist circumference, body weight, and height were collected
    using standard procedures during physical examinations. SBP and DBP were calculated
    as the arithmetic averages of repeated measures (up to 4 times) for each participant.
    TGs and HDL-c were measured in serum, while fasting glucose was measured in plasma.'
  prefs: []
  type: TYPE_NORMAL
- en: Covariates Assessment
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
- en: NHANES collects some sociodemographic information through structured data. The
    main covariates in this study were demographic characteristics and chronic comorbidities.
    Demographic characteristics, including age, sex, race, and education level, were
    reported by interviewees. Measurements of waist size, weight, and height were
    taken by well-trained health technologists following the anthropometry procedure
    manual. Body mass index (BMI) was calculated as weight (kg) divided by height
    squared (m²). Currently used clinical criteria and guidelines issued by the International
    Diabetes Association were used to diagnose diabetes, with diabetes classified
    by either fasting blood glucose greater than or equal to 7.0 mmol/L in laboratory
    tests, blood glucose greater than 11.1 mmol/L in the oral glucose tolerance test
    experiment, those taking diabetes medications, those diagnosed with diabetes by
    their doctors during the survey, and those who self-reported. Hypertension was
    defined as a mean SBP greater than or equal to 140 mm Hg or DBP greater than or
    equal to 90 mm Hg or current use of antihypertensive medication as per self-reported
    questionnaire. Other chronic comorbidities such as hyperlipidemia were identified
    either through a doctor's diagnosis or a self-reported questionnaire.
  prefs: []
  type: TYPE_NORMAL
- en: Statistical Analyses
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
- en: 'For all individuals in the present study, descriptive analyses were performed
    on the characteristics of each participant. Statistical analysis was conducted
    using R open-source software version 4.3.1 to analyze the data for this study.
    Data extraction and analyses were performed with the use of the “nhanesR” package
    of R software(R Core Team; 2023\. R: A Language and Environment for Statistical
    Computing. R Foundation for Statistical Computing, [https://www.R-project.org/](https://www.R-project.org/)).
    For continuous variables, the mean and SD were reported, while for categorical
    variables, percentages were reported. For continuous variables, the baseline characteristics
    were analyzed using a linear regression model, and for categorical variables,
    they were analyzed using a chi-square test. Weighted univariate and multivariable
    logistic regression were used to assess the association between MDS and MetS.
    The formulas for multivariable logistic regression were: log(p/(1 − p)) = β0 +
    β1X1 + β2X2 + … + βnXn (where p = probability of MetS, β0 = intercept, β1 to βn
    = regression coefficients for each predictor variable, X1 to Xn = predictor variables
    (age, sex, race, etc). Four models were created: a crude model with no adjustments
    for confounding factors; model 1, adjusted for age, sex, race, and education level;
    model 2, adjusted for the variables in model 1 plus BMI, waist, alanine transaminase
    (ALT), aspartate transaminase (AST), TGs, total cholesterol (TC), HDL-c, low-density
    lipoprotein cholesterol (LDL-c), homeostatic model assessment for insulin resistance
    (HOMA-IR), glycated hemoglobin A[1c] (HbA[1c]), corrected calcium (Ca), smoking,
    and drinking; and model 3, adjusted for the variables in model 2 plus hyperlipidemia,
    diabetes, and hypertension. Restricted cubic spline (RCS) analysis was conducted
    to characterize dose-response relationships. Stratified analyses by sociodemographic
    and lifestyle factors were also performed. We considered all survey sampling weights
    when analyzing the data, which were considered statistically significant if *P*
    was less than .05.'
  prefs: []
  type: TYPE_NORMAL
- en: Results
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
- en: Baseline Characteristics of Study Participants by Metabolic Syndrome
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
- en: Between 2003 and 2018, a total of 80 312 participants were involved in NHANES
    (see Fig. 1). Participants who did not provide relevant information for the calculation
    of MetS, MDS, or other variables were excluded, resulting in a final sample of
    15 565 participants for statistical analysis. Of these, 10 127 did not have MetS,
    while 5438 did. In Table 1, we show the general characteristics of the study population
    based on whether they had MetS. Compared to individuals without MetS, those with
    MetS were found to be more likely older, of non-Hispanic white ethnicity, smokers,
    nondrinkers, and with a lower education level. They also exhibited higher BMI,
    waist circumference, ALT, AST, TGs, TC, LDL-c, and MDS, but lower eGFR. Furthermore,
    individuals with MetS demonstrated more severe insulin resistance, higher levels
    of HbA[1c], and were more likely to have a history of hyperlipidemia, hypertension,
    and diabetes. MDS was categorized into 6 levels from 0 to 5\. The proportion of
    participants with MDS = 0 was lower in the MetS group compared to the non-MetS
    group (32.48% vs 49.41%), while the proportions for MDS greater than or equal
    to 2 were all higher in the MetS group (all *P* < .05).
  prefs: []
  type: TYPE_NORMAL
- en: Table 1.
  prefs: []
  type: TYPE_NORMAL
- en: Baseline characteristics of participants with or without metabolic syndrome
  prefs: []
  type: TYPE_NORMAL
- en: '| Characters . | Total . | Non–metabolic syndrome . | Metabolic syndrome .
    | *P* . |'
  prefs: []
  type: TYPE_TB
- en: '| --- | --- | --- | --- | --- |'
  prefs: []
  type: TYPE_TB
- en: '| Age, y | 47.3 ± 0.3 | 43.7 ± 0.3 | 54.7 ± 0.3 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Sex |  |  |  | .06 |'
  prefs: []
  type: TYPE_TB
- en: '|  Male | 7823 (49.78%) | 5278 (50.54%) | 2545 (48.20%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Female | 7744 (50.22%) | 4851 (49.46%) | 2893 (51.80%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| Race |  |  |  | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  Non-Hispanic White | 7029 (69.83%) | 4411 (68.37%) | 2618 (72.85%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Non-Hispanic Black | 3115 (10.15%) | 2108 (10.66%) | 1007 (9.09%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Mexican American | 2544 (8.24%) | 1613 (8.35%) | 931 (8.03%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Other race | 2879 (11.78%) | 1997 (12.62%) | 882 (10.03%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| Education |  |  |  | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  > High school | 8029 (59.90%) | 5539 (62.99%) | 2490 (53.50%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  High school | 5955 (34.89%) | 3704 (32.42%) | 2251 (39.99%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  < High school | 1583 (5.21%) | 886 (4.59%) | 697 (6.51%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| BMI | 28.83 ± 0.09 | 26.70 ± 0.09 | 33.25 ± 0.15 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Waist, cm | 98.88 ± 0.23 | 92.94 ± 0.21 | 111.18 ± 0.33 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| MDS | 0.83 ± 0.01 | 0.67 ± 0.01 | 1.16 ± 0.02 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| MDS |  |  |  | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  0 | 7135 (44.23%) | 5366 (49.91%) | 1769 (32.48%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  1 | 5057 (35.79%) | 3352 (36.76%) | 1705 (33.78%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  2 | 2292 (14.23%) | 1087 (10.65%) | 1205 (21.65%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  3 | 885 (4.67%) | 276 (2.25%) | 609 (9.66%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  4 | 192 (1.05%) | 45 (0.41%) | 147 (2.39%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  5 | 6 (0.03%) | 3 (0.02%) | 3 (0.03%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| ALT, U/L | 25.27 ± 0.17 | 23.77 ± 0.18 | 28.37 ± 0.34 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| AST, U/L | 25.07 ± 0.16 | 24.60 ± 0.16 | 26.04 ± 0.29 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| TGs, mmol/L | 1.35 ± 0.01 | 1.09 ± 0.01 | 1.90 ± 0.02 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| TC, mmol/L | 5.01 ± 0.01 | 4.99 ± 0.01 | 5.06 ± 0.02 | **.002** |'
  prefs: []
  type: TYPE_TB
- en: '| HDL-c, mmol/L | 1.41 ± 0.01 | 1.51 ± 0.01 | 1.21 ± 0.01 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| LDL-c, mmol/L | 2.96 ± 0.01 | 2.94 ± 0.01 | 2.99 ± 0.02 | **.02** |'
  prefs: []
  type: TYPE_TB
- en: '| eGFR, mL/min/1.73 m² | 94.86 ± 0.34 | 98.22 ± 0.36 | 87.90 ± 0.48 | **<.0001**
    |'
  prefs: []
  type: TYPE_TB
- en: '| HOMA-IR | 3.45 ± 0.05 | 2.25 ± 0.03 | 5.95 ± 0.12 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| HbA[1c], % | 5.58 ± 0.01 | 5.37 ± 0.01 | 6.02 ± 0.02 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Ca, mg/dL | 9.14 ± 0.01 | 9.11 ± 0.01 | 9.20 ± 0.01 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Smoking |  |  |  | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  No | 8524 (54.21%) | 5780 (56.56%) | 2744 (49.36%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 7043 (45.79%) | 4349 (43.44%) | 2694 (50.64%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| Drinking |  |  |  | **<.001** |'
  prefs: []
  type: TYPE_TB
- en: '|  No | 2188 (10.92%) | 1331 (10.27%) | 857 (12.27%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 13 379 (89.08%) | 8798 (89.73%) | 4581 (87.73%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| Hyperlipidemia |  |  |  | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  No | 4454 (29.54%) | 4076 (40.54%) | 378 (6.78%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 11 113 (70.46%) | 6053 (59.46%) | 5060 (93.22%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| Hypertension |  |  |  | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  No | 9062 (62.69%) | 7357 (76.53%) | 1705 (34.06%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 6505 (37.31%) | 2772 (23.47%) | 3733 (65.94%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| Diabetes |  |  |  | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  No | 12 534 (85.20%) | 9364 (94.97%) | 3170 (64.97%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 3033 (14.80%) | 765( 5.03%) | 2268 (35.03%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| Characters . | Total . | Non–metabolic syndrome . | Metabolic syndrome .
    | *P* . |'
  prefs: []
  type: TYPE_TB
- en: '| --- | --- | --- | --- | --- |'
  prefs: []
  type: TYPE_TB
- en: '| Age, y | 47.3 ± 0.3 | 43.7 ± 0.3 | 54.7 ± 0.3 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Sex |  |  |  | .06 |'
  prefs: []
  type: TYPE_TB
- en: '|  Male | 7823 (49.78%) | 5278 (50.54%) | 2545 (48.20%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Female | 7744 (50.22%) | 4851 (49.46%) | 2893 (51.80%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| Race |  |  |  | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  Non-Hispanic White | 7029 (69.83%) | 4411 (68.37%) | 2618 (72.85%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Non-Hispanic Black | 3115 (10.15%) | 2108 (10.66%) | 1007 (9.09%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Mexican American | 2544 (8.24%) | 1613 (8.35%) | 931 (8.03%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Other race | 2879 (11.78%) | 1997 (12.62%) | 882 (10.03%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| Education |  |  |  | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  > High school | 8029 (59.90%) | 5539 (62.99%) | 2490 (53.50%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  High school | 5955 (34.89%) | 3704 (32.42%) | 2251 (39.99%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  < High school | 1583 (5.21%) | 886 (4.59%) | 697 (6.51%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| BMI | 28.83 ± 0.09 | 26.70 ± 0.09 | 33.25 ± 0.15 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Waist, cm | 98.88 ± 0.23 | 92.94 ± 0.21 | 111.18 ± 0.33 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| MDS | 0.83 ± 0.01 | 0.67 ± 0.01 | 1.16 ± 0.02 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| MDS |  |  |  | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  0 | 7135 (44.23%) | 5366 (49.91%) | 1769 (32.48%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  1 | 5057 (35.79%) | 3352 (36.76%) | 1705 (33.78%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  2 | 2292 (14.23%) | 1087 (10.65%) | 1205 (21.65%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  3 | 885 (4.67%) | 276 (2.25%) | 609 (9.66%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  4 | 192 (1.05%) | 45 (0.41%) | 147 (2.39%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  5 | 6 (0.03%) | 3 (0.02%) | 3 (0.03%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| ALT, U/L | 25.27 ± 0.17 | 23.77 ± 0.18 | 28.37 ± 0.34 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| AST, U/L | 25.07 ± 0.16 | 24.60 ± 0.16 | 26.04 ± 0.29 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| TGs, mmol/L | 1.35 ± 0.01 | 1.09 ± 0.01 | 1.90 ± 0.02 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| TC, mmol/L | 5.01 ± 0.01 | 4.99 ± 0.01 | 5.06 ± 0.02 | **.002** |'
  prefs: []
  type: TYPE_TB
- en: '| HDL-c, mmol/L | 1.41 ± 0.01 | 1.51 ± 0.01 | 1.21 ± 0.01 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| LDL-c, mmol/L | 2.96 ± 0.01 | 2.94 ± 0.01 | 2.99 ± 0.02 | **.02** |'
  prefs: []
  type: TYPE_TB
- en: '| eGFR, mL/min/1.73 m² | 94.86 ± 0.34 | 98.22 ± 0.36 | 87.90 ± 0.48 | **<.0001**
    |'
  prefs: []
  type: TYPE_TB
- en: '| HOMA-IR | 3.45 ± 0.05 | 2.25 ± 0.03 | 5.95 ± 0.12 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| HbA[1c], % | 5.58 ± 0.01 | 5.37 ± 0.01 | 6.02 ± 0.02 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Ca, mg/dL | 9.14 ± 0.01 | 9.11 ± 0.01 | 9.20 ± 0.01 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Smoking |  |  |  | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  No | 8524 (54.21%) | 5780 (56.56%) | 2744 (49.36%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 7043 (45.79%) | 4349 (43.44%) | 2694 (50.64%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| Drinking |  |  |  | **<.001** |'
  prefs: []
  type: TYPE_TB
- en: '|  No | 2188 (10.92%) | 1331 (10.27%) | 857 (12.27%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 13 379 (89.08%) | 8798 (89.73%) | 4581 (87.73%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| Hyperlipidemia |  |  |  | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  No | 4454 (29.54%) | 4076 (40.54%) | 378 (6.78%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 11 113 (70.46%) | 6053 (59.46%) | 5060 (93.22%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| Hypertension |  |  |  | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  No | 9062 (62.69%) | 7357 (76.53%) | 1705 (34.06%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 6505 (37.31%) | 2772 (23.47%) | 3733 (65.94%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| Diabetes |  |  |  | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  No | 12 534 (85.20%) | 9364 (94.97%) | 3170 (64.97%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 3033 (14.80%) | 765( 5.03%) | 2268 (35.03%) |  |'
  prefs: []
  type: TYPE_TB
- en: Table 1.
  prefs: []
  type: TYPE_NORMAL
- en: Baseline characteristics of participants with or without metabolic syndrome
  prefs: []
  type: TYPE_NORMAL
- en: '| Characters . | Total . | Non–metabolic syndrome . | Metabolic syndrome .
    | *P* . |'
  prefs: []
  type: TYPE_TB
- en: '| --- | --- | --- | --- | --- |'
  prefs: []
  type: TYPE_TB
- en: '| Age, y | 47.3 ± 0.3 | 43.7 ± 0.3 | 54.7 ± 0.3 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Sex |  |  |  | .06 |'
  prefs: []
  type: TYPE_TB
- en: '|  Male | 7823 (49.78%) | 5278 (50.54%) | 2545 (48.20%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Female | 7744 (50.22%) | 4851 (49.46%) | 2893 (51.80%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| Race |  |  |  | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  Non-Hispanic White | 7029 (69.83%) | 4411 (68.37%) | 2618 (72.85%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Non-Hispanic Black | 3115 (10.15%) | 2108 (10.66%) | 1007 (9.09%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Mexican American | 2544 (8.24%) | 1613 (8.35%) | 931 (8.03%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Other race | 2879 (11.78%) | 1997 (12.62%) | 882 (10.03%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| Education |  |  |  | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  > High school | 8029 (59.90%) | 5539 (62.99%) | 2490 (53.50%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  High school | 5955 (34.89%) | 3704 (32.42%) | 2251 (39.99%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  < High school | 1583 (5.21%) | 886 (4.59%) | 697 (6.51%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| BMI | 28.83 ± 0.09 | 26.70 ± 0.09 | 33.25 ± 0.15 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Waist, cm | 98.88 ± 0.23 | 92.94 ± 0.21 | 111.18 ± 0.33 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| MDS | 0.83 ± 0.01 | 0.67 ± 0.01 | 1.16 ± 0.02 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| MDS |  |  |  | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  0 | 7135 (44.23%) | 5366 (49.91%) | 1769 (32.48%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  1 | 5057 (35.79%) | 3352 (36.76%) | 1705 (33.78%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  2 | 2292 (14.23%) | 1087 (10.65%) | 1205 (21.65%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  3 | 885 (4.67%) | 276 (2.25%) | 609 (9.66%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  4 | 192 (1.05%) | 45 (0.41%) | 147 (2.39%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  5 | 6 (0.03%) | 3 (0.02%) | 3 (0.03%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| ALT, U/L | 25.27 ± 0.17 | 23.77 ± 0.18 | 28.37 ± 0.34 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| AST, U/L | 25.07 ± 0.16 | 24.60 ± 0.16 | 26.04 ± 0.29 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| TGs, mmol/L | 1.35 ± 0.01 | 1.09 ± 0.01 | 1.90 ± 0.02 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| TC, mmol/L | 5.01 ± 0.01 | 4.99 ± 0.01 | 5.06 ± 0.02 | **.002** |'
  prefs: []
  type: TYPE_TB
- en: '| HDL-c, mmol/L | 1.41 ± 0.01 | 1.51 ± 0.01 | 1.21 ± 0.01 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| LDL-c, mmol/L | 2.96 ± 0.01 | 2.94 ± 0.01 | 2.99 ± 0.02 | **.02** |'
  prefs: []
  type: TYPE_TB
- en: '| eGFR, mL/min/1.73 m² | 94.86 ± 0.34 | 98.22 ± 0.36 | 87.90 ± 0.48 | **<.0001**
    |'
  prefs: []
  type: TYPE_TB
- en: '| HOMA-IR | 3.45 ± 0.05 | 2.25 ± 0.03 | 5.95 ± 0.12 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| HbA[1c], % | 5.58 ± 0.01 | 5.37 ± 0.01 | 6.02 ± 0.02 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Ca, mg/dL | 9.14 ± 0.01 | 9.11 ± 0.01 | 9.20 ± 0.01 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Smoking |  |  |  | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  No | 8524 (54.21%) | 5780 (56.56%) | 2744 (49.36%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 7043 (45.79%) | 4349 (43.44%) | 2694 (50.64%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| Drinking |  |  |  | **<.001** |'
  prefs: []
  type: TYPE_TB
- en: '|  No | 2188 (10.92%) | 1331 (10.27%) | 857 (12.27%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 13 379 (89.08%) | 8798 (89.73%) | 4581 (87.73%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| Hyperlipidemia |  |  |  | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  No | 4454 (29.54%) | 4076 (40.54%) | 378 (6.78%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 11 113 (70.46%) | 6053 (59.46%) | 5060 (93.22%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| Hypertension |  |  |  | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  No | 9062 (62.69%) | 7357 (76.53%) | 1705 (34.06%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 6505 (37.31%) | 2772 (23.47%) | 3733 (65.94%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| Diabetes |  |  |  | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  No | 12 534 (85.20%) | 9364 (94.97%) | 3170 (64.97%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 3033 (14.80%) | 765( 5.03%) | 2268 (35.03%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| Characters . | Total . | Non–metabolic syndrome . | Metabolic syndrome .
    | *P* . |'
  prefs: []
  type: TYPE_TB
- en: '| --- | --- | --- | --- | --- |'
  prefs: []
  type: TYPE_TB
- en: '| Age, y | 47.3 ± 0.3 | 43.7 ± 0.3 | 54.7 ± 0.3 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Sex |  |  |  | .06 |'
  prefs: []
  type: TYPE_TB
- en: '|  Male | 7823 (49.78%) | 5278 (50.54%) | 2545 (48.20%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Female | 7744 (50.22%) | 4851 (49.46%) | 2893 (51.80%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| Race |  |  |  | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  Non-Hispanic White | 7029 (69.83%) | 4411 (68.37%) | 2618 (72.85%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Non-Hispanic Black | 3115 (10.15%) | 2108 (10.66%) | 1007 (9.09%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Mexican American | 2544 (8.24%) | 1613 (8.35%) | 931 (8.03%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Other race | 2879 (11.78%) | 1997 (12.62%) | 882 (10.03%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| Education |  |  |  | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  > High school | 8029 (59.90%) | 5539 (62.99%) | 2490 (53.50%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  High school | 5955 (34.89%) | 3704 (32.42%) | 2251 (39.99%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  < High school | 1583 (5.21%) | 886 (4.59%) | 697 (6.51%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| BMI | 28.83 ± 0.09 | 26.70 ± 0.09 | 33.25 ± 0.15 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Waist, cm | 98.88 ± 0.23 | 92.94 ± 0.21 | 111.18 ± 0.33 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| MDS | 0.83 ± 0.01 | 0.67 ± 0.01 | 1.16 ± 0.02 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| MDS |  |  |  | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  0 | 7135 (44.23%) | 5366 (49.91%) | 1769 (32.48%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  1 | 5057 (35.79%) | 3352 (36.76%) | 1705 (33.78%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  2 | 2292 (14.23%) | 1087 (10.65%) | 1205 (21.65%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  3 | 885 (4.67%) | 276 (2.25%) | 609 (9.66%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  4 | 192 (1.05%) | 45 (0.41%) | 147 (2.39%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  5 | 6 (0.03%) | 3 (0.02%) | 3 (0.03%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| ALT, U/L | 25.27 ± 0.17 | 23.77 ± 0.18 | 28.37 ± 0.34 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| AST, U/L | 25.07 ± 0.16 | 24.60 ± 0.16 | 26.04 ± 0.29 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| TGs, mmol/L | 1.35 ± 0.01 | 1.09 ± 0.01 | 1.90 ± 0.02 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| TC, mmol/L | 5.01 ± 0.01 | 4.99 ± 0.01 | 5.06 ± 0.02 | **.002** |'
  prefs: []
  type: TYPE_TB
- en: '| HDL-c, mmol/L | 1.41 ± 0.01 | 1.51 ± 0.01 | 1.21 ± 0.01 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| LDL-c, mmol/L | 2.96 ± 0.01 | 2.94 ± 0.01 | 2.99 ± 0.02 | **.02** |'
  prefs: []
  type: TYPE_TB
- en: '| eGFR, mL/min/1.73 m² | 94.86 ± 0.34 | 98.22 ± 0.36 | 87.90 ± 0.48 | **<.0001**
    |'
  prefs: []
  type: TYPE_TB
- en: '| HOMA-IR | 3.45 ± 0.05 | 2.25 ± 0.03 | 5.95 ± 0.12 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| HbA[1c], % | 5.58 ± 0.01 | 5.37 ± 0.01 | 6.02 ± 0.02 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Ca, mg/dL | 9.14 ± 0.01 | 9.11 ± 0.01 | 9.20 ± 0.01 | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Smoking |  |  |  | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  No | 8524 (54.21%) | 5780 (56.56%) | 2744 (49.36%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 7043 (45.79%) | 4349 (43.44%) | 2694 (50.64%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| Drinking |  |  |  | **<.001** |'
  prefs: []
  type: TYPE_TB
- en: '|  No | 2188 (10.92%) | 1331 (10.27%) | 857 (12.27%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 13 379 (89.08%) | 8798 (89.73%) | 4581 (87.73%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| Hyperlipidemia |  |  |  | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  No | 4454 (29.54%) | 4076 (40.54%) | 378 (6.78%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 11 113 (70.46%) | 6053 (59.46%) | 5060 (93.22%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| Hypertension |  |  |  | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  No | 9062 (62.69%) | 7357 (76.53%) | 1705 (34.06%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 6505 (37.31%) | 2772 (23.47%) | 3733 (65.94%) |  |'
  prefs: []
  type: TYPE_TB
- en: '| Diabetes |  |  |  | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  No | 12 534 (85.20%) | 9364 (94.97%) | 3170 (64.97%) |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 3033 (14.80%) | 765( 5.03%) | 2268 (35.03%) |  |'
  prefs: []
  type: TYPE_TB
- en: Univariate Logistic Regression for Factors Associated With Metabolic Syndrome
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
- en: In Table 2, we show the results of univariate logistic regression analysis assessing
    the association between various factors and MetS. The MDS was found to be significantly
    associated with increased odds of MetS. The odds ratio (OR) for MDS was 1.78 (95%
    CI, 1.69-1.88), indicating that every 1-unit increase in MDS was associated with
    78% higher odds of having MetS. When MDS was categorized into 6 levels, there
    was a stepwise increase in the odds of MetS with increasing MDS. Using MDS = 0
    as reference, the OR (95% CI) was 1.41 (1.28-1.56) for MDS = 1; 3.12 (2.71-3.59)
    for MDS = 2; 6.59 (5.28-8.24) for MDS = 3; and 9.05 (5.97-13.73) for MDS = 4\.
    The association was statistically significant for MDS levels ranging from 1 to
    4 (all *P* < .0001). Other factors significantly associated with higher odds of
    MetS included older age, non-Hispanic White race, lower education level, higher
    BMI, larger waist circumference, elevated levels of ALT, AST, TGs, TC, LDL-c,
    HOMA-IR, HbA[1c], smoking, no alcohol drinking, and the presence of hyperlipidemia,
    hypertension, and diabetes (all *P* < .05).
  prefs: []
  type: TYPE_NORMAL
- en: Table 2.
  prefs: []
  type: TYPE_NORMAL
- en: Univariate logistics regression analysis of the association between magnesium
    depletion score and metabolic syndrome
  prefs: []
  type: TYPE_NORMAL
- en: '| Character . | OR (95% CI) . | *P* . |'
  prefs: []
  type: TYPE_TB
- en: '| --- | --- | --- |'
  prefs: []
  type: TYPE_TB
- en: '| Age, y | 1.04 (1.04-1.04) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Sex |'
  prefs: []
  type: TYPE_TB
- en: '|  Male | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  Female | 1.10 (1.00-1.21) | .06 |'
  prefs: []
  type: TYPE_TB
- en: '| Race |'
  prefs: []
  type: TYPE_TB
- en: '|  Non-Hispanic White | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  Non-Hispanic Black | 0.80 (0.72-0.89) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  Mexican American | 0.90 (0.79-1.03) | .12 |'
  prefs: []
  type: TYPE_TB
- en: '|  Other Race | 0.75 (0.65-0.85) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Education |'
  prefs: []
  type: TYPE_TB
- en: '|  > High school | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  High school | 1.45 (1.30-1.62) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  < High school | 1.67 (1.42-1.97) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| BMI | 1.19 (1.17-1.20) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Waist, cm | 1.09 (1.09-1.10) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| MDS | 1.78 (1.69-1.88) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  0 | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  1 | 1.41 (1.28-1.56) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  2 | 3.12 (2.71-3.59) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  3 | 6.59 (5.28-8.24) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  4 | 9.05 (5.97-13.73) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  5 | 1.76 (0.32-9.56) | .51 |'
  prefs: []
  type: TYPE_TB
- en: '| ALT, U/L | 1.02 (1.01-1.02) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| AST, U/L | 1.01 (1.00-1.01) | **.002** |'
  prefs: []
  type: TYPE_TB
- en: '| TGs, mmol/L | 5.42 (4.86-6.04) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| TC, mmol/L | 1.07 (1.02-1.12) | **.002** |'
  prefs: []
  type: TYPE_TB
- en: '| HDL-c, mmol/L | 0.08 (0.07-0.10) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| LDL-c, mmol/L | 1.06 (1.01-1.11) | **.02** |'
  prefs: []
  type: TYPE_TB
- en: '| HOMA-IR | 1.59 (1.53-1.65) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| HbA[1c], % | 3.82 (3.34-4.37) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Ca, mg/dL | 2.29 (1.96-2.68) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Smoking |'
  prefs: []
  type: TYPE_TB
- en: '|  No | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 1.34 (1.23-1.45) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Drinking |'
  prefs: []
  type: TYPE_TB
- en: '|  No | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 0.82 (0.73-0.92) | **<.001** |'
  prefs: []
  type: TYPE_TB
- en: '| Hyperlipidemia |'
  prefs: []
  type: TYPE_TB
- en: '|  No | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 9.37 (7.80-11.26) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Hypertension |'
  prefs: []
  type: TYPE_TB
- en: '|  No | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 6.31 (5.65-7.05) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Diabetes |'
  prefs: []
  type: TYPE_TB
- en: '|  No | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 10.18 (8.92-11.62) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Character . | OR (95% CI) . | *P* . |'
  prefs: []
  type: TYPE_TB
- en: '| --- | --- | --- |'
  prefs: []
  type: TYPE_TB
- en: '| Age, y | 1.04 (1.04-1.04) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Sex |'
  prefs: []
  type: TYPE_TB
- en: '|  Male | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  Female | 1.10 (1.00-1.21) | .06 |'
  prefs: []
  type: TYPE_TB
- en: '| Race |'
  prefs: []
  type: TYPE_TB
- en: '|  Non-Hispanic White | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  Non-Hispanic Black | 0.80 (0.72-0.89) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  Mexican American | 0.90 (0.79-1.03) | .12 |'
  prefs: []
  type: TYPE_TB
- en: '|  Other Race | 0.75 (0.65-0.85) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Education |'
  prefs: []
  type: TYPE_TB
- en: '|  > High school | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  High school | 1.45 (1.30-1.62) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  < High school | 1.67 (1.42-1.97) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| BMI | 1.19 (1.17-1.20) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Waist, cm | 1.09 (1.09-1.10) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| MDS | 1.78 (1.69-1.88) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  0 | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  1 | 1.41 (1.28-1.56) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  2 | 3.12 (2.71-3.59) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  3 | 6.59 (5.28-8.24) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  4 | 9.05 (5.97-13.73) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  5 | 1.76 (0.32-9.56) | .51 |'
  prefs: []
  type: TYPE_TB
- en: '| ALT, U/L | 1.02 (1.01-1.02) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| AST, U/L | 1.01 (1.00-1.01) | **.002** |'
  prefs: []
  type: TYPE_TB
- en: '| TGs, mmol/L | 5.42 (4.86-6.04) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| TC, mmol/L | 1.07 (1.02-1.12) | **.002** |'
  prefs: []
  type: TYPE_TB
- en: '| HDL-c, mmol/L | 0.08 (0.07-0.10) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| LDL-c, mmol/L | 1.06 (1.01-1.11) | **.02** |'
  prefs: []
  type: TYPE_TB
- en: '| HOMA-IR | 1.59 (1.53-1.65) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| HbA[1c], % | 3.82 (3.34-4.37) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Ca, mg/dL | 2.29 (1.96-2.68) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Smoking |'
  prefs: []
  type: TYPE_TB
- en: '|  No | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 1.34 (1.23-1.45) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Drinking |'
  prefs: []
  type: TYPE_TB
- en: '|  No | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 0.82 (0.73-0.92) | **<.001** |'
  prefs: []
  type: TYPE_TB
- en: '| Hyperlipidemia |'
  prefs: []
  type: TYPE_TB
- en: '|  No | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 9.37 (7.80-11.26) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Hypertension |'
  prefs: []
  type: TYPE_TB
- en: '|  No | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 6.31 (5.65-7.05) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Diabetes |'
  prefs: []
  type: TYPE_TB
- en: '|  No | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 10.18 (8.92-11.62) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: Table 2.
  prefs: []
  type: TYPE_NORMAL
- en: Univariate logistics regression analysis of the association between magnesium
    depletion score and metabolic syndrome
  prefs: []
  type: TYPE_NORMAL
- en: '| Character . | OR (95% CI) . | *P* . |'
  prefs: []
  type: TYPE_TB
- en: '| --- | --- | --- |'
  prefs: []
  type: TYPE_TB
- en: '| Age, y | 1.04 (1.04-1.04) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Sex |'
  prefs: []
  type: TYPE_TB
- en: '|  Male | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  Female | 1.10 (1.00-1.21) | .06 |'
  prefs: []
  type: TYPE_TB
- en: '| Race |'
  prefs: []
  type: TYPE_TB
- en: '|  Non-Hispanic White | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  Non-Hispanic Black | 0.80 (0.72-0.89) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  Mexican American | 0.90 (0.79-1.03) | .12 |'
  prefs: []
  type: TYPE_TB
- en: '|  Other Race | 0.75 (0.65-0.85) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Education |'
  prefs: []
  type: TYPE_TB
- en: '|  > High school | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  High school | 1.45 (1.30-1.62) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  < High school | 1.67 (1.42-1.97) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| BMI | 1.19 (1.17-1.20) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Waist, cm | 1.09 (1.09-1.10) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| MDS | 1.78 (1.69-1.88) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  0 | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  1 | 1.41 (1.28-1.56) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  2 | 3.12 (2.71-3.59) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  3 | 6.59 (5.28-8.24) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  4 | 9.05 (5.97-13.73) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  5 | 1.76 (0.32-9.56) | .51 |'
  prefs: []
  type: TYPE_TB
- en: '| ALT, U/L | 1.02 (1.01-1.02) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| AST, U/L | 1.01 (1.00-1.01) | **.002** |'
  prefs: []
  type: TYPE_TB
- en: '| TGs, mmol/L | 5.42 (4.86-6.04) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| TC, mmol/L | 1.07 (1.02-1.12) | **.002** |'
  prefs: []
  type: TYPE_TB
- en: '| HDL-c, mmol/L | 0.08 (0.07-0.10) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| LDL-c, mmol/L | 1.06 (1.01-1.11) | **.02** |'
  prefs: []
  type: TYPE_TB
- en: '| HOMA-IR | 1.59 (1.53-1.65) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| HbA[1c], % | 3.82 (3.34-4.37) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Ca, mg/dL | 2.29 (1.96-2.68) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Smoking |'
  prefs: []
  type: TYPE_TB
- en: '|  No | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 1.34 (1.23-1.45) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Drinking |'
  prefs: []
  type: TYPE_TB
- en: '|  No | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 0.82 (0.73-0.92) | **<.001** |'
  prefs: []
  type: TYPE_TB
- en: '| Hyperlipidemia |'
  prefs: []
  type: TYPE_TB
- en: '|  No | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 9.37 (7.80-11.26) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Hypertension |'
  prefs: []
  type: TYPE_TB
- en: '|  No | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 6.31 (5.65-7.05) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Diabetes |'
  prefs: []
  type: TYPE_TB
- en: '|  No | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 10.18 (8.92-11.62) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Character . | OR (95% CI) . | *P* . |'
  prefs: []
  type: TYPE_TB
- en: '| --- | --- | --- |'
  prefs: []
  type: TYPE_TB
- en: '| Age, y | 1.04 (1.04-1.04) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Sex |'
  prefs: []
  type: TYPE_TB
- en: '|  Male | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  Female | 1.10 (1.00-1.21) | .06 |'
  prefs: []
  type: TYPE_TB
- en: '| Race |'
  prefs: []
  type: TYPE_TB
- en: '|  Non-Hispanic White | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  Non-Hispanic Black | 0.80 (0.72-0.89) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  Mexican American | 0.90 (0.79-1.03) | .12 |'
  prefs: []
  type: TYPE_TB
- en: '|  Other Race | 0.75 (0.65-0.85) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Education |'
  prefs: []
  type: TYPE_TB
- en: '|  > High school | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  High school | 1.45 (1.30-1.62) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  < High school | 1.67 (1.42-1.97) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| BMI | 1.19 (1.17-1.20) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Waist, cm | 1.09 (1.09-1.10) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| MDS | 1.78 (1.69-1.88) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  0 | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  1 | 1.41 (1.28-1.56) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  2 | 3.12 (2.71-3.59) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  3 | 6.59 (5.28-8.24) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  4 | 9.05 (5.97-13.73) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '|  5 | 1.76 (0.32-9.56) | .51 |'
  prefs: []
  type: TYPE_TB
- en: '| ALT, U/L | 1.02 (1.01-1.02) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| AST, U/L | 1.01 (1.00-1.01) | **.002** |'
  prefs: []
  type: TYPE_TB
- en: '| TGs, mmol/L | 5.42 (4.86-6.04) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| TC, mmol/L | 1.07 (1.02-1.12) | **.002** |'
  prefs: []
  type: TYPE_TB
- en: '| HDL-c, mmol/L | 0.08 (0.07-0.10) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| LDL-c, mmol/L | 1.06 (1.01-1.11) | **.02** |'
  prefs: []
  type: TYPE_TB
- en: '| HOMA-IR | 1.59 (1.53-1.65) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| HbA[1c], % | 3.82 (3.34-4.37) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Ca, mg/dL | 2.29 (1.96-2.68) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Smoking |'
  prefs: []
  type: TYPE_TB
- en: '|  No | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 1.34 (1.23-1.45) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Drinking |'
  prefs: []
  type: TYPE_TB
- en: '|  No | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 0.82 (0.73-0.92) | **<.001** |'
  prefs: []
  type: TYPE_TB
- en: '| Hyperlipidemia |'
  prefs: []
  type: TYPE_TB
- en: '|  No | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 9.37 (7.80-11.26) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Hypertension |'
  prefs: []
  type: TYPE_TB
- en: '|  No | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 6.31 (5.65-7.05) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| Diabetes |'
  prefs: []
  type: TYPE_TB
- en: '|  No | Reference | Reference |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 10.18 (8.92-11.62) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: Multivariable Logistic Regression Models for the Association Between Magnesium
    Depletion Score and Metabolic Syndrome
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
- en: Table 3 presents the results of multivariable logistic regression analysis of
    the association between MDS and MetS using 4 models. In the crude model without
    adjustments, a higher MDS was significantly associated with increased odds of
    MetS. The OR (95% CI) for each 1-unit increase in MDS was 1.78 (1.69-1.88). When
    MDS was categorized into 6 levels, there was a graded increase in the odds of
    MetS with increasing MDS (*P* for trend <.0001). After adjusting for demographics
    (age, sex, race, and education) in model 1, the association between MDS and MetS
    was attenuated but remained significant. The OR (95% CI) for each 1-unit increase
    in MDS was 1.33 (1.25-1.41). The odds were also significantly higher for MDS levels
    2 to 4 compared to MDS = 0\. With further adjustments for various cardiometabolic
    factors in models 2 and 3, the association between MDS and MetS persisted. In
    the fully adjusted model 3, the OR (95% CI) for each 1-unit increase in MDS was
    1.31 (1.17-1.45). MDS levels 1 to 4 remained significantly associated with higher
    odds of MetS compared to MDS = 0 after full adjustments (all *P* < .05).
  prefs: []
  type: TYPE_NORMAL
- en: Table 3.
  prefs: []
  type: TYPE_NORMAL
- en: Multivariable logistics regression analysis of the association between magnesium
    depletion score and metabolic syndrome
  prefs: []
  type: TYPE_NORMAL
- en: '| Character . | Model . |'
  prefs: []
  type: TYPE_TB
- en: '| --- | --- |'
  prefs: []
  type: TYPE_TB
- en: '| Crude model . | Model 1 . | Model 2 . | Model 3 . |'
  prefs: []
  type: TYPE_TB
- en: '| --- | --- | --- | --- |'
  prefs: []
  type: TYPE_TB
- en: '| 95% CI . | *P* . | 95% CI . | *P* . | 95% CI . | *P* . | 95% CI . | *P* .
    |'
  prefs: []
  type: TYPE_TB
- en: '| --- | --- | --- | --- | --- | --- | --- | --- |'
  prefs: []
  type: TYPE_TB
- en: '| Total | 1.78 (1.69-1.88) | **<.0001** | 1.33 (1.25-1.41) | **<.0001** | 1.51
    (1.37-1.67) | **<.0001** | 1.31 (1.17-1.45) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| 0 | Reference |  | Reference |  | Reference |  | Reference |  |'
  prefs: []
  type: TYPE_TB
- en: '| 1 | 1.41 (1.28-1.56) | **<.0001** | 1.00 (0.89-1.11) | .96 | 1.32 (1.10-1.57)
    | **.003** | 1.28 (1.06-1.55) | **.01** |'
  prefs: []
  type: TYPE_TB
- en: '| 2 | 3.12 (2.71-3.59) | **<.0001** | 1.60 (1.37-1.87) | **<.0001** | 2.10
    (1.65-2.68) | **<.0001** | 1.57 (1.22-2.03) | **<.001** |'
  prefs: []
  type: TYPE_TB
- en: '| 3 | 6.59 (5.28-8.24) | **<.0001** | 2.70 (2.09-3.48) | **<.0001** | 4.19
    (2.78-6.33) | **<.0001** | 2.60 (1.69-4.02) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| 4 | 9.05 (5.97-13.73) | **<.0001** | 3.49 (2.24-5.44) | **<.0001** | 4.76
    (2.53-8.94) | **<.0001** | 2.83 (1.42-5.61) | **.003** |'
  prefs: []
  type: TYPE_TB
- en: '| 5 | 1.76 (0.32-9.56) | .51 | 0.59 (0.10-3.36) | .55 | 1.39 (0.12-15.59) |
    .79 | 0.88 (0.07-11.47) | .92 |'
  prefs: []
  type: TYPE_TB
- en: '| *P* for trend |  | **<.0001** |  | **<.0001** |  | **<.0001** |  | **<.0001**
    |'
  prefs: []
  type: TYPE_TB
- en: '| Character . | Model . |'
  prefs: []
  type: TYPE_TB
- en: '| --- | --- |'
  prefs: []
  type: TYPE_TB
- en: '| Crude model . | Model 1 . | Model 2 . | Model 3 . |'
  prefs: []
  type: TYPE_TB
- en: '| --- | --- | --- | --- |'
  prefs: []
  type: TYPE_TB
- en: '| 95% CI . | *P* . | 95% CI . | *P* . | 95% CI . | *P* . | 95% CI . | *P* .
    |'
  prefs: []
  type: TYPE_TB
- en: '| --- | --- | --- | --- | --- | --- | --- | --- |'
  prefs: []
  type: TYPE_TB
- en: '| Total | 1.78 (1.69-1.88) | **<.0001** | 1.33 (1.25-1.41) | **<.0001** | 1.51
    (1.37-1.67) | **<.0001** | 1.31 (1.17-1.45) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| 0 | Reference |  | Reference |  | Reference |  | Reference |  |'
  prefs: []
  type: TYPE_TB
- en: '| 1 | 1.41 (1.28-1.56) | **<.0001** | 1.00 (0.89-1.11) | .96 | 1.32 (1.10-1.57)
    | **.003** | 1.28 (1.06-1.55) | **.01** |'
  prefs: []
  type: TYPE_TB
- en: '| 2 | 3.12 (2.71-3.59) | **<.0001** | 1.60 (1.37-1.87) | **<.0001** | 2.10
    (1.65-2.68) | **<.0001** | 1.57 (1.22-2.03) | **<.001** |'
  prefs: []
  type: TYPE_TB
- en: '| 3 | 6.59 (5.28-8.24) | **<.0001** | 2.70 (2.09-3.48) | **<.0001** | 4.19
    (2.78-6.33) | **<.0001** | 2.60 (1.69-4.02) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| 4 | 9.05 (5.97-13.73) | **<.0001** | 3.49 (2.24-5.44) | **<.0001** | 4.76
    (2.53-8.94) | **<.0001** | 2.83 (1.42-5.61) | **.003** |'
  prefs: []
  type: TYPE_TB
- en: '| 5 | 1.76 (0.32-9.56) | .51 | 0.59 (0.10-3.36) | .55 | 1.39 (0.12-15.59) |
    .79 | 0.88 (0.07-11.47) | .92 |'
  prefs: []
  type: TYPE_TB
- en: '| *P* for trend |  | **<.0001** |  | **<.0001** |  | **<.0001** |  | **<.0001**
    |'
  prefs: []
  type: TYPE_TB
- en: Table 3.
  prefs: []
  type: TYPE_NORMAL
- en: Multivariable logistics regression analysis of the association between magnesium
    depletion score and metabolic syndrome
  prefs: []
  type: TYPE_NORMAL
- en: '| Character . | Model . |'
  prefs: []
  type: TYPE_TB
- en: '| --- | --- |'
  prefs: []
  type: TYPE_TB
- en: '| Crude model . | Model 1 . | Model 2 . | Model 3 . |'
  prefs: []
  type: TYPE_TB
- en: '| --- | --- | --- | --- |'
  prefs: []
  type: TYPE_TB
- en: '| 95% CI . | *P* . | 95% CI . | *P* . | 95% CI . | *P* . | 95% CI . | *P* .
    |'
  prefs: []
  type: TYPE_TB
- en: '| --- | --- | --- | --- | --- | --- | --- | --- |'
  prefs: []
  type: TYPE_TB
- en: '| Total | 1.78 (1.69-1.88) | **<.0001** | 1.33 (1.25-1.41) | **<.0001** | 1.51
    (1.37-1.67) | **<.0001** | 1.31 (1.17-1.45) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| 0 | Reference |  | Reference |  | Reference |  | Reference |  |'
  prefs: []
  type: TYPE_TB
- en: '| 1 | 1.41 (1.28-1.56) | **<.0001** | 1.00 (0.89-1.11) | .96 | 1.32 (1.10-1.57)
    | **.003** | 1.28 (1.06-1.55) | **.01** |'
  prefs: []
  type: TYPE_TB
- en: '| 2 | 3.12 (2.71-3.59) | **<.0001** | 1.60 (1.37-1.87) | **<.0001** | 2.10
    (1.65-2.68) | **<.0001** | 1.57 (1.22-2.03) | **<.001** |'
  prefs: []
  type: TYPE_TB
- en: '| 3 | 6.59 (5.28-8.24) | **<.0001** | 2.70 (2.09-3.48) | **<.0001** | 4.19
    (2.78-6.33) | **<.0001** | 2.60 (1.69-4.02) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| 4 | 9.05 (5.97-13.73) | **<.0001** | 3.49 (2.24-5.44) | **<.0001** | 4.76
    (2.53-8.94) | **<.0001** | 2.83 (1.42-5.61) | **.003** |'
  prefs: []
  type: TYPE_TB
- en: '| 5 | 1.76 (0.32-9.56) | .51 | 0.59 (0.10-3.36) | .55 | 1.39 (0.12-15.59) |
    .79 | 0.88 (0.07-11.47) | .92 |'
  prefs: []
  type: TYPE_TB
- en: '| *P* for trend |  | **<.0001** |  | **<.0001** |  | **<.0001** |  | **<.0001**
    |'
  prefs: []
  type: TYPE_TB
- en: '| Character . | Model . |'
  prefs: []
  type: TYPE_TB
- en: '| --- | --- |'
  prefs: []
  type: TYPE_TB
- en: '| Crude model . | Model 1 . | Model 2 . | Model 3 . |'
  prefs: []
  type: TYPE_TB
- en: '| --- | --- | --- | --- |'
  prefs: []
  type: TYPE_TB
- en: '| 95% CI . | *P* . | 95% CI . | *P* . | 95% CI . | *P* . | 95% CI . | *P* .
    |'
  prefs: []
  type: TYPE_TB
- en: '| --- | --- | --- | --- | --- | --- | --- | --- |'
  prefs: []
  type: TYPE_TB
- en: '| Total | 1.78 (1.69-1.88) | **<.0001** | 1.33 (1.25-1.41) | **<.0001** | 1.51
    (1.37-1.67) | **<.0001** | 1.31 (1.17-1.45) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| 0 | Reference |  | Reference |  | Reference |  | Reference |  |'
  prefs: []
  type: TYPE_TB
- en: '| 1 | 1.41 (1.28-1.56) | **<.0001** | 1.00 (0.89-1.11) | .96 | 1.32 (1.10-1.57)
    | **.003** | 1.28 (1.06-1.55) | **.01** |'
  prefs: []
  type: TYPE_TB
- en: '| 2 | 3.12 (2.71-3.59) | **<.0001** | 1.60 (1.37-1.87) | **<.0001** | 2.10
    (1.65-2.68) | **<.0001** | 1.57 (1.22-2.03) | **<.001** |'
  prefs: []
  type: TYPE_TB
- en: '| 3 | 6.59 (5.28-8.24) | **<.0001** | 2.70 (2.09-3.48) | **<.0001** | 4.19
    (2.78-6.33) | **<.0001** | 2.60 (1.69-4.02) | **<.0001** |'
  prefs: []
  type: TYPE_TB
- en: '| 4 | 9.05 (5.97-13.73) | **<.0001** | 3.49 (2.24-5.44) | **<.0001** | 4.76
    (2.53-8.94) | **<.0001** | 2.83 (1.42-5.61) | **.003** |'
  prefs: []
  type: TYPE_TB
- en: '| 5 | 1.76 (0.32-9.56) | .51 | 0.59 (0.10-3.36) | .55 | 1.39 (0.12-15.59) |
    .79 | 0.88 (0.07-11.47) | .92 |'
  prefs: []
  type: TYPE_TB
- en: '| *P* for trend |  | **<.0001** |  | **<.0001** |  | **<.0001** |  | **<.0001**
    |'
  prefs: []
  type: TYPE_TB
- en: Stratified Analysis of the Association Between Magnesium Depletion Score and
    Metabolic Syndrome
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
- en: This study examined the association between MDS and MetS across subgroups defined
    by age, sex, race, BMI, drinking status, and smoking status using multivariable
    logistic regression analysis adjusted for potential confounders (Table 4). MDS
    was significantly associated with increased odds of MetS in most subgroups, with
    ORs ranging from 1.19 to 1.60 per 1-unit MDS increase. The association was not
    significant only in the Mexican American subgroup (*P* = .08). There was no significant
    interaction detected between MDS and subgroups, indicating the positive MDS-MetS
    relationship was consistent across diverse population segments. Overall, these
    findings demonstrate that higher magnesium deficiency status as reflected by MDS
    is a robust independent risk factor for MetS irrespective of sociodemographic
    and lifestyle factors in US adults.
  prefs: []
  type: TYPE_NORMAL
- en: Table 4.
  prefs: []
  type: TYPE_NORMAL
- en: Subgroup analysis for the association between magnesium depletion score and
    metabolic syndrome
  prefs: []
  type: TYPE_NORMAL
- en: '| Character . | OR (95% CI) . | *P* . | *P* for interaction . |'
  prefs: []
  type: TYPE_TB
- en: '| --- | --- | --- | --- |'
  prefs: []
  type: TYPE_TB
- en: '| Age, y |  |  | .33 |'
  prefs: []
  type: TYPE_TB
- en: '|  <40 | 1.26 (1.01-1.58) | **.04** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  40-60 | 1.28 (1.09-1.51) | **.003** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  >60 | 1.33 (1.18-1.51) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '| Sex |  |  | .46 |'
  prefs: []
  type: TYPE_TB
- en: '|  Male | 1.60 (1.40-1.83) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Female | 1.48 (1.30-1.69) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '| Race |  |  | .27 |'
  prefs: []
  type: TYPE_TB
- en: '|  Non-Hispanic White | 1.51 (1.34-1.70) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Non-Hispanic Black | 1.38 (1.22-1.56) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Mexican American | 1.19 (0.98-1.46) | .08 |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Other race | 1.37 (1.13-1.65) | **.001** |  |'
  prefs: []
  type: TYPE_TB
- en: '| BMI |  |  | .92 |'
  prefs: []
  type: TYPE_TB
- en: '|  Normal | 1.33 (1.02-1.74) | **.03** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Unnormal | 1.50 (1.36-1.64) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '| Drinking |  |  | .27 |'
  prefs: []
  type: TYPE_TB
- en: '|  No | 1.43 (1.19-1.73) | **<.001** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 1.50 (1.37-1.64) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '| Smoking |  |  | .75 |'
  prefs: []
  type: TYPE_TB
- en: '|  No | 1.57 (1.38-1.78) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 1.42 (1.26-1.60) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '| Character . | OR (95% CI) . | *P* . | *P* for interaction . |'
  prefs: []
  type: TYPE_TB
- en: '| --- | --- | --- | --- |'
  prefs: []
  type: TYPE_TB
- en: '| Age, y |  |  | .33 |'
  prefs: []
  type: TYPE_TB
- en: '|  <40 | 1.26 (1.01-1.58) | **.04** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  40-60 | 1.28 (1.09-1.51) | **.003** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  >60 | 1.33 (1.18-1.51) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '| Sex |  |  | .46 |'
  prefs: []
  type: TYPE_TB
- en: '|  Male | 1.60 (1.40-1.83) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Female | 1.48 (1.30-1.69) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '| Race |  |  | .27 |'
  prefs: []
  type: TYPE_TB
- en: '|  Non-Hispanic White | 1.51 (1.34-1.70) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Non-Hispanic Black | 1.38 (1.22-1.56) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Mexican American | 1.19 (0.98-1.46) | .08 |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Other race | 1.37 (1.13-1.65) | **.001** |  |'
  prefs: []
  type: TYPE_TB
- en: '| BMI |  |  | .92 |'
  prefs: []
  type: TYPE_TB
- en: '|  Normal | 1.33 (1.02-1.74) | **.03** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Unnormal | 1.50 (1.36-1.64) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '| Drinking |  |  | .27 |'
  prefs: []
  type: TYPE_TB
- en: '|  No | 1.43 (1.19-1.73) | **<.001** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 1.50 (1.37-1.64) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '| Smoking |  |  | .75 |'
  prefs: []
  type: TYPE_TB
- en: '|  No | 1.57 (1.38-1.78) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 1.42 (1.26-1.60) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: Table 4.
  prefs: []
  type: TYPE_NORMAL
- en: Subgroup analysis for the association between magnesium depletion score and
    metabolic syndrome
  prefs: []
  type: TYPE_NORMAL
- en: '| Character . | OR (95% CI) . | *P* . | *P* for interaction . |'
  prefs: []
  type: TYPE_TB
- en: '| --- | --- | --- | --- |'
  prefs: []
  type: TYPE_TB
- en: '| Age, y |  |  | .33 |'
  prefs: []
  type: TYPE_TB
- en: '|  <40 | 1.26 (1.01-1.58) | **.04** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  40-60 | 1.28 (1.09-1.51) | **.003** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  >60 | 1.33 (1.18-1.51) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '| Sex |  |  | .46 |'
  prefs: []
  type: TYPE_TB
- en: '|  Male | 1.60 (1.40-1.83) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Female | 1.48 (1.30-1.69) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '| Race |  |  | .27 |'
  prefs: []
  type: TYPE_TB
- en: '|  Non-Hispanic White | 1.51 (1.34-1.70) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Non-Hispanic Black | 1.38 (1.22-1.56) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Mexican American | 1.19 (0.98-1.46) | .08 |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Other race | 1.37 (1.13-1.65) | **.001** |  |'
  prefs: []
  type: TYPE_TB
- en: '| BMI |  |  | .92 |'
  prefs: []
  type: TYPE_TB
- en: '|  Normal | 1.33 (1.02-1.74) | **.03** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Unnormal | 1.50 (1.36-1.64) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '| Drinking |  |  | .27 |'
  prefs: []
  type: TYPE_TB
- en: '|  No | 1.43 (1.19-1.73) | **<.001** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 1.50 (1.37-1.64) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '| Smoking |  |  | .75 |'
  prefs: []
  type: TYPE_TB
- en: '|  No | 1.57 (1.38-1.78) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 1.42 (1.26-1.60) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '| Character . | OR (95% CI) . | *P* . | *P* for interaction . |'
  prefs: []
  type: TYPE_TB
- en: '| --- | --- | --- | --- |'
  prefs: []
  type: TYPE_TB
- en: '| Age, y |  |  | .33 |'
  prefs: []
  type: TYPE_TB
- en: '|  <40 | 1.26 (1.01-1.58) | **.04** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  40-60 | 1.28 (1.09-1.51) | **.003** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  >60 | 1.33 (1.18-1.51) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '| Sex |  |  | .46 |'
  prefs: []
  type: TYPE_TB
- en: '|  Male | 1.60 (1.40-1.83) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Female | 1.48 (1.30-1.69) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '| Race |  |  | .27 |'
  prefs: []
  type: TYPE_TB
- en: '|  Non-Hispanic White | 1.51 (1.34-1.70) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Non-Hispanic Black | 1.38 (1.22-1.56) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Mexican American | 1.19 (0.98-1.46) | .08 |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Other race | 1.37 (1.13-1.65) | **.001** |  |'
  prefs: []
  type: TYPE_TB
- en: '| BMI |  |  | .92 |'
  prefs: []
  type: TYPE_TB
- en: '|  Normal | 1.33 (1.02-1.74) | **.03** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Unnormal | 1.50 (1.36-1.64) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '| Drinking |  |  | .27 |'
  prefs: []
  type: TYPE_TB
- en: '|  No | 1.43 (1.19-1.73) | **<.001** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 1.50 (1.37-1.64) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '| Smoking |  |  | .75 |'
  prefs: []
  type: TYPE_TB
- en: '|  No | 1.57 (1.38-1.78) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: '|  Yes | 1.42 (1.26-1.60) | **<.0001** |  |'
  prefs: []
  type: TYPE_TB
- en: 'Magnesium Depletion Score and Odds of Metabolic Syndrome: A Restricted Cubic
    Spline Analysis'
  prefs:
  - PREF_H3
  type: TYPE_NORMAL
- en: As shown in Fig. 2, RCS was drawn to visually describe the relationship between
    MDS and MetS. The OR increased steadily with higher MDS up to a level of around
    4, where the OR peaked. Beyond MDS of 4, the OR plateaued and slightly declined
    with further increases in MDS. The *P* value for a nonlinear relationship was
    greater than .05, indicating there was no statistically significant evidence of
    nonlinearity between MDS and MetS odds. Although the OR appeared to peak at MDS
    of 4, the overall relationship can be considered linear given the nonsignificant
    test for nonlinearity. In summary, this figure demonstrates an approximately linear-positive
    association between higher MDS and increased odds of MetS, without clear threshold
    effects.
  prefs: []
  type: TYPE_NORMAL
- en: Figure 2.
  prefs: []
  type: TYPE_NORMAL
- en: Nonlinear associations between magnesium depletion score (MDS) and risk of metabolic
    syndrome (MetS). The restricted cubic spline plot between MDS and MetS. The x-axis
    represents MDS, while the y-axis represents the odds ratio (OR) and the 95% CI
    for MetS. The dashed line indicates an OR of 1, which represents no association
    between MDS and MetS risk. The model adjusted by age, sex, race, body mass index,
    waist, alanine transaminase, aspartate transaminase, triglycerides, total cholesterol,
    high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, homeostatic
    model assessment for insulin resistance, glycated hemoglobin A[1c], corrected
    calcium, smoking, drinking, hyperlipidemia, diabetes, and hypertension.
  prefs: []
  type: TYPE_NORMAL
- en: Discussion
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
- en: Based on NHANES data from 2003 to 2018, we investigated the relationship between
    MetS and MDS among US adults. We found that higher MDS, indicative of greater
    urinary magnesium loss, was independently associated with increased likelihood
    of MetS. We observed a graded dose-response relationship between MDS and the odds
    of MetS, with no evidence of a threshold effect. The positive correlation between
    MDS and MetS remained significant even after adjusting for potential sociodemographic,
    lifestyle, and cardiometabolic confounders. This association was consistently
    observed across various subgroups defined by age, sex, race, BMI, drinking status,
    and smoking status.
  prefs: []
  type: TYPE_NORMAL
- en: MetS is a constellation of multiple risk factors, including insulin resistance,
    dyslipidemia, hypertension, and adiposity (17). Magnesium is an essential nutrient
    for maintaining vital physiological functions. Numerous studies have investigated
    the relationship between MetS and magnesium. An increasing body of evidence suggests
    that chronic hypomagnesemia may play a role in the pathogenesis of various metabolic
    disorders, including overweight and obesity, insulin resistance, and type 2 diabetes
    mellitus, hypertension, alterations in lipid metabolism, and low-grade inflammation
    (18-20). A randomized, double-blind, placebo-controlled clinical trial show that
    oral magnesium supplementation improves incident MetS with a significant reduction
    in high blood pressure, hyperglycemia, and hypertriglyceridemia (21). In conclusion,
    magnesium plays a substantial role in MetS occurrence and development.
  prefs: []
  type: TYPE_NORMAL
- en: Serum magnesium is the most commonly used approach to evaluate magnesium status
    in clinical practice. However, it does not accurately reflect the total-body magnesium
    levels. The serum magnesium level is typically within the normal reference range,
    especially in the case of chronic magnesium deficiency (22, 23). The serum contains
    0.3% of the body's total magnesium, and the rest is primarily stored in bones,
    muscles, and soft tissue (24). Both urinary magnesium levels and the fractional
    excretion of magnesium (FEMg) serve as methods for assessing magnesium status.
    The FEMg is calculated using the concentrations of magnesium and creatinine both
    in serum and urine, and can serve as a useful tool in assessing magnesium status
    (25). However, both urinary magnesium and FEMg are easily influenced by various
    factors such as renal function and dietary intake (26). The magnesium tolerance
    test is regarded as a gold standard for evaluating the magnesium status of the
    body, but it is impractical and difficult to apply broadly since it requires a
    first 24-hour urine collection, intravenous magnesium infusion, and then a second
    24-hour urine collection (27, 28). The oral magnesium loading test is another
    method for assessing magnesium deficiency. This noninvasive procedure merely requires
    the oral intake of magnesium and urine collection. However, it necessitates the
    collection of urine over a specific duration, typically 24 hours, which can pose
    an inconvenience for the patient. This factor may restrict its utilization in
    routine clinical practice (29). Although intense research activities have been
    dedicated to magnesium, the difficulties of accessing total-body magnesium, and
    its main 2 compartments, namely bone and muscle, mean that today there is still
    no simple, rapid, and accurate laboratory test to indicate total-body magnesium
    status in humans (28). The MDS has been demonstrated as a good indicator for predicting
    magnesium deficiency validated by a magnesium tolerance test (12). It is a simple
    and easy tool to evaluate magnesium deficiency. This implies that the incorporation
    of MDS with other methods for assessing magnesium status could potentially enhance
    our ability to effectively identify individuals with magnesium deficiency.
  prefs: []
  type: TYPE_NORMAL
- en: The MDS combines 4 risk factors affecting magnesium reabsorption in the US population,
    including alcohol consumption, diuretics, PPI, and kidney function (12). For instance,
    alcohol consumption causes a prompt increase in the urinary excretion of magnesium
    (30). Similarly, diuretics can enhance magnesium excretion (31). The administration
    of a PPI has been shown to reduce kidney reabsorption of magnesium by downregulating
    TRPM6 activity (32). In addition to alcohol and medication use, magnesium reabsorption
    in the kidney can be drastically altered under certain pathophysiological conditions.
    Chronic kidney disease is accompanied by increased renal magnesium-wasting (33)
    and, thus, impaired kidney function has been recognized as an essential pathway
    underlying magnesium depletion from the urine. Overall, these factors contribute
    to the utility of MDS as a comprehensive measurement tool for evaluating the status
    of magnesium.
  prefs: []
  type: TYPE_NORMAL
- en: To our knowledge, there have been no studies investigating the association between
    magnesium deficiency, assessed using an easy-to-use tool like the MDS, and MetS.
  prefs: []
  type: TYPE_NORMAL
- en: In this study, we discovered a positive association between the MDS, a newly
    developed assessment metric for magnesium status, and MetS. Our findings are supported
    by some clinical research. A systematic review and meta-analysis evaluated the
    theory that a higher magnesium intake is associated with a lower risk of MetS
    (9 articles, n = 31 876, OR = 0.73; 95% CI, 0.62-0.86; *P* < .001) (34). Other
    evidence suggests that dietary magnesium has beneficial effects, including regulating
    systemic inflammation (35) and hypertension (36), regulating lipids (37), glucose
    and insulin metabolism, improving insulin sensitivity (38), and reducing the risk
    of diabetes (39). However, data regarding the association between magnesium status
    and MetS are conflicting. Some studies concluded that serum magnesium levels are
    lower in patients with MetS compared with their controls (40), whereas other studies
    reported a nonsignificant association (41) or even proposed that there may be
    a positive association between serum magnesium concentration and MetS (42). In
    hypertension, a similar situation exists. A systematic review and meta-analysis
    of prospective cohort studies found an inverse association between dietary magnesium
    intake and the risk of hypertension comparing the highest intake group with the
    lowest. However, the association of serum magnesium concentration with the risk
    of hypertension was marginally significant (36). This may be because serum magnesium
    cannot reflect the actual status of whole-body magnesium levels. Therefore, it
    is very important to find an indicator of the supplement of serum magnesium, to
    better reflect the status of magnesium levels in the body.
  prefs: []
  type: TYPE_NORMAL
- en: This study sheds light on the issue of magnesium deficiency and uncovers a positive
    correlation between MDS and the risk of MetS. The results imply that we need to
    be vigilant about MetS risk, especially for patients with a higher MDS. This allows
    us to identify individuals in the community who may be in a magnesium-deficient
    state through the use of MDS and other assessment methods, and provide magnesium
    supplementation to these populations to reduce the incidence of MetS.
  prefs: []
  type: TYPE_NORMAL
- en: Our study has several advantages. This is the first large, national study to
    investigate the association between MDS and MetS based on the well-designed NHNAES
    data. It is worth noting that the analysis incorporates the use of sampling weights
    assigned to each participant. These weights play a crucial role in enabling statistical
    inferences and generalizing our findings to a larger population beyond the sample
    size of MetS cases. By accounting for these weights, our study ensures reliable
    conclusions and precise statistical power. In addition, a stratified subgroup
    analysis was conducted to further investigate the relationship between MDS and
    MetS across different population groups, which suggests that we need to implement
    more precise prevention strategies for MetS. Furthermore, MDS rather than serum
    magnesium was used in our study, which is more reflective of the physiological
    state of magnesium.
  prefs: []
  type: TYPE_NORMAL
- en: This study also has some limitations that need to be clarified. First, we observed
    that there is a nonsignificant association between MDS and Mets when MDS = 5\.
    This may be attributable to the small number of participants with MDS = 5, which
    totaled only 6 individuals. Second, we did not evaluate whether MDS was a “better”
    indicator of magnesium deficiency compared to serum magnesium levels because of
    the lack of serum magnesium in NHANES. Furthermore, the cross-sectional study
    design cannot definitively determine causation between MDS and MetS. It is also
    worth noting that MDS is a categorical variable, not a continuous variable. In
    addition, while MDS includes PPI and diuretics, other drugs such as tetracyclines,
    bisphosphonates, β-adrenergic agonists, insulin, etc, which can affect magnesium
    levels (31), are not accounted for in MDS. Last, although several covariates were
    adjusted to investigate the association between MDS and MetS, potential confounders
    that might have effects on the results were not included.
  prefs: []
  type: TYPE_NORMAL
- en: In conclusion, our study identified a significant association between MDS and
    MetS, and further explored differences across various subgroups. In addition to
    having major implications for clinical practice, our findings have important public
    health implications as well. It is possible to prevent and reduce MetS by supplementing
    with magnesium supplements or encouraging higher magnesium intake diet because
    diet is a factor that can be changed.
  prefs: []
  type: TYPE_NORMAL
- en: Acknowledgments
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
- en: The author thanks the staff and the participants of the NHANES study for their
    valuable contributions.
  prefs: []
  type: TYPE_NORMAL
- en: Funding
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
- en: This work was supported by the National Natural Science Foundation of China
    (grant Nos. 82371572 and 82170842 to Zhen Liang and No. 82171556 to Lin Kang)
    and the Natural Science Foundation of Shenzhen Municipality (No. KCXFZ20201221173600001
    to Zhen Liang).
  prefs: []
  type: TYPE_NORMAL
- en: Disclosures
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
- en: All contributing authors have approved the final manuscript version and report
    no conflicts of interest.
  prefs: []
  type: TYPE_NORMAL
- en: Data Availability
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
- en: Publicly available data sets were analyzed in this study. These data can be
    found at [https://www.cdc.gov/nchs/nhanes/index.htm](https://www.cdc.gov/nchs/nhanes/index.htm).
  prefs: []
  type: TYPE_NORMAL
- en: References
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
- en: '1'
  prefs: []
  type: TYPE_NORMAL
- en: Eckel
  prefs: []
  type: TYPE_NORMAL
- en: RH
  prefs: []
  type: TYPE_NORMAL
- en: ', Grundy'
  prefs: []
  type: TYPE_NORMAL
- en: SM , Zimmet
  prefs: []
  type: TYPE_NORMAL
- en: PZ .
  prefs: []
  type: TYPE_NORMAL
- en: The metabolic syndrome
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Lancet
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2005'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '365'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '9468'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '1415'
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: '1428'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2'
  prefs: []
  type: TYPE_NORMAL
- en: Lebovitz
  prefs: []
  type: TYPE_NORMAL
- en: HE
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: 'Insulin resistance: definition and consequences'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Exp Clin Endocrinol Diabetes
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2001'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '109'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: Suppl 2
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: S135
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: S148
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '3'
  prefs: []
  type: TYPE_NORMAL
- en: Haffner
  prefs: []
  type: TYPE_NORMAL
- en: SM
  prefs: []
  type: TYPE_NORMAL
- en: ', Valdez'
  prefs: []
  type: TYPE_NORMAL
- en: RA , Hazuda
  prefs: []
  type: TYPE_NORMAL
- en: HP , Mitchell
  prefs: []
  type: TYPE_NORMAL
- en: BD , Morales
  prefs: []
  type: TYPE_NORMAL
- en: PA , Stern
  prefs: []
  type: TYPE_NORMAL
- en: MP .
  prefs: []
  type: TYPE_NORMAL
- en: Prospective analysis of the insulin-resistance syndrome (syndrome X)
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Diabetes
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '1992'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '41'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '6'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '715'
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: '722'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '4'
  prefs: []
  type: TYPE_NORMAL
- en: Alberti
  prefs: []
  type: TYPE_NORMAL
- en: KGMM
  prefs: []
  type: TYPE_NORMAL
- en: ', Zimmet'
  prefs: []
  type: TYPE_NORMAL
- en: PZ .
  prefs: []
  type: TYPE_NORMAL
- en: 'Definition, diagnosis and classification of diabetes mellitus and its complications.
    Part 1: diagnosis and classification of diabetes mellitus provisional report of
    a WHO consultation'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Diabet Med
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '1998'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '15'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '7'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '539'
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: '553'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '5'
  prefs: []
  type: TYPE_NORMAL
- en: Grundy
  prefs: []
  type: TYPE_NORMAL
- en: SM
  prefs: []
  type: TYPE_NORMAL
- en: ', Brewer'
  prefs: []
  type: TYPE_NORMAL
- en: HB
  prefs: []
  type: TYPE_NORMAL
- en: Jr, Cleeman
  prefs: []
  type: TYPE_NORMAL
- en: JI , Smith
  prefs: []
  type: TYPE_NORMAL
- en: SC
  prefs: []
  type: TYPE_NORMAL
- en: Jr, Lenfant
  prefs: []
  type: TYPE_NORMAL
- en: C .
  prefs: []
  type: TYPE_NORMAL
- en: 'Definition of metabolic syndrome: report of the National Heart, Lung, and Blood
    Institute/American Heart Association conference on scientific issues related to
    definition'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Circulation
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2004'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '109'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '3'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '433'
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: '438'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '6'
  prefs: []
  type: TYPE_NORMAL
- en: Tangvoraphonkchai
  prefs: []
  type: TYPE_NORMAL
- en: K
  prefs: []
  type: TYPE_NORMAL
- en: ', Davenport'
  prefs: []
  type: TYPE_NORMAL
- en: A .
  prefs: []
  type: TYPE_NORMAL
- en: Magnesium and cardiovascular disease
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Adv Chronic Kidney Dis
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2018'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '25'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '3'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '251'
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: '260'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '7'
  prefs: []
  type: TYPE_NORMAL
- en: Pickering
  prefs: []
  type: TYPE_NORMAL
- en: G
  prefs: []
  type: TYPE_NORMAL
- en: ', Mazur'
  prefs: []
  type: TYPE_NORMAL
- en: A , Trousselard
  prefs: []
  type: TYPE_NORMAL
- en: M , et al.
  prefs: []
  type: TYPE_NORMAL
- en: 'Magnesium status and stress: the vicious circle concept revisited'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Nutrients
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2020'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '12'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '12'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '3672'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '8'
  prefs: []
  type: TYPE_NORMAL
- en: Tarleton
  prefs: []
  type: TYPE_NORMAL
- en: EK
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Factors influencing magnesium consumption among adults in the United States
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Nutr Rev
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2018'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '76'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '7'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '526'
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: '538'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '9'
  prefs: []
  type: TYPE_NORMAL
- en: Wu
  prefs: []
  type: TYPE_NORMAL
- en: J
  prefs: []
  type: TYPE_NORMAL
- en: ', Xun'
  prefs: []
  type: TYPE_NORMAL
- en: P , Tang
  prefs: []
  type: TYPE_NORMAL
- en: Q , Cai
  prefs: []
  type: TYPE_NORMAL
- en: W , He
  prefs: []
  type: TYPE_NORMAL
- en: K .
  prefs: []
  type: TYPE_NORMAL
- en: 'Circulating magnesium levels and incidence of coronary heart diseases, hypertension,
    and type 2 diabetes mellitus: a meta-analysis of prospective cohort studies'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Nutr J
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2017'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '16'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '1'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '60'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '10'
  prefs: []
  type: TYPE_NORMAL
- en: Oost
  prefs: []
  type: TYPE_NORMAL
- en: LJ
  prefs: []
  type: TYPE_NORMAL
- en: ', Tack'
  prefs: []
  type: TYPE_NORMAL
- en: CJ , de Baaij
  prefs: []
  type: TYPE_NORMAL
- en: JHF .
  prefs: []
  type: TYPE_NORMAL
- en: Hypomagnesemia and cardiovascular risk in type 2 diabetes
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Endocr Rev
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2023'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '44'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '3'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '357'
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: '378'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '11'
  prefs: []
  type: TYPE_NORMAL
- en: Xing
  prefs: []
  type: TYPE_NORMAL
- en: B
  prefs: []
  type: TYPE_NORMAL
- en: ', Xu'
  prefs: []
  type: TYPE_NORMAL
- en: X , Li
  prefs: []
  type: TYPE_NORMAL
- en: C , Zhao
  prefs: []
  type: TYPE_NORMAL
- en: Y , Wang
  prefs: []
  type: TYPE_NORMAL
- en: Y , Zhao
  prefs: []
  type: TYPE_NORMAL
- en: W .
  prefs: []
  type: TYPE_NORMAL
- en: 'Reduced serum magnesium levels are associated with the occurrence of retinopathy
    in patients with type 2 diabetes mellitus: a retrospective study'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Biol Trace Elem Res
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2022'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '200'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '5'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '2025'
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: '2032'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '12'
  prefs: []
  type: TYPE_NORMAL
- en: Fan
  prefs: []
  type: TYPE_NORMAL
- en: L
  prefs: []
  type: TYPE_NORMAL
- en: ', Zhu'
  prefs: []
  type: TYPE_NORMAL
- en: X , Rosanoff
  prefs: []
  type: TYPE_NORMAL
- en: A , et al.
  prefs: []
  type: TYPE_NORMAL
- en: Magnesium depletion score (MDS) predicts risk of systemic inflammation and cardiovascular
    mortality among US adults
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: J Nutr
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2021'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '151'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '8'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '2226'
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: '2235'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '13'
  prefs: []
  type: TYPE_NORMAL
- en: Woteki
  prefs: []
  type: TYPE_NORMAL
- en: CE
  prefs: []
  type: TYPE_NORMAL
- en: ', Briefel'
  prefs: []
  type: TYPE_NORMAL
- en: RR , Kuczmarski
  prefs: []
  type: TYPE_NORMAL
- en: R .
  prefs: []
  type: TYPE_NORMAL
- en: Federal monitoring of the nation's nutritional status. Contributions of the
    National Center for Health Statistics
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Am J Clin Nutr
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '1988'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '47'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '2'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '320'
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: '328'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '14'
  prefs: []
  type: TYPE_NORMAL
- en: Liu
  prefs: []
  type: TYPE_NORMAL
- en: H
  prefs: []
  type: TYPE_NORMAL
- en: ', Tan'
  prefs: []
  type: TYPE_NORMAL
- en: X , Liu
  prefs: []
  type: TYPE_NORMAL
- en: Z , et al.
  prefs: []
  type: TYPE_NORMAL
- en: 'Association between diet-related inflammation and COPD: findings from NHANES
    III'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Front Nutr
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2021'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '8'
  prefs: []
  type: TYPE_NORMAL
- en: ':'
  prefs: []
  type: TYPE_NORMAL
- en: '732099'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '15'
  prefs: []
  type: TYPE_NORMAL
- en: Gong
  prefs: []
  type: TYPE_NORMAL
- en: R
  prefs: []
  type: TYPE_NORMAL
- en: ', Pu'
  prefs: []
  type: TYPE_NORMAL
- en: X , Cheng
  prefs: []
  type: TYPE_NORMAL
- en: Z , Ding
  prefs: []
  type: TYPE_NORMAL
- en: J , Chen
  prefs: []
  type: TYPE_NORMAL
- en: Z , Wang
  prefs: []
  type: TYPE_NORMAL
- en: Y .
  prefs: []
  type: TYPE_NORMAL
- en: 'The association between serum cadmium and diabetes in the general population:
    a cross-sectional study from NHANES (1999–2020)'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Front Nutr
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2022'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '9'
  prefs: []
  type: TYPE_NORMAL
- en: ':'
  prefs: []
  type: TYPE_NORMAL
- en: '966500'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '16'
  prefs: []
  type: TYPE_NORMAL
- en: Levey
  prefs: []
  type: TYPE_NORMAL
- en: AS
  prefs: []
  type: TYPE_NORMAL
- en: ', Stevens'
  prefs: []
  type: TYPE_NORMAL
- en: LA , Schmid
  prefs: []
  type: TYPE_NORMAL
- en: CH , et al.
  prefs: []
  type: TYPE_NORMAL
- en: A new equation to estimate glomerular filtration rate
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Ann Intern Med
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2009'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '150'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '9'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '604'
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: '612'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '17'
  prefs: []
  type: TYPE_NORMAL
- en: Wang
  prefs: []
  type: TYPE_NORMAL
- en: Q
  prefs: []
  type: TYPE_NORMAL
- en: ', Oliver-Williams'
  prefs: []
  type: TYPE_NORMAL
- en: C , Raitakari
  prefs: []
  type: TYPE_NORMAL
- en: OT , et al.
  prefs: []
  type: TYPE_NORMAL
- en: 'Metabolic profiling of angiopoietin-like protein 3 and 4 inhibition: a drug-target
    Mendelian randomization analysis'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Eur Heart J
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2021'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '42'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '12'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '1160'
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: '1169'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '18'
  prefs: []
  type: TYPE_NORMAL
- en: Fang
  prefs: []
  type: TYPE_NORMAL
- en: X
  prefs: []
  type: TYPE_NORMAL
- en: ', Wang'
  prefs: []
  type: TYPE_NORMAL
- en: K , Han
  prefs: []
  type: TYPE_NORMAL
- en: D , et al.
  prefs: []
  type: TYPE_NORMAL
- en: 'Dietary magnesium intake and the risk of cardiovascular disease, type 2 diabetes,
    and all-cause mortality: a dose-response meta-analysis of prospective cohort studies'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: BMC Med
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2016'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '14'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '1'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '210'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '19'
  prefs: []
  type: TYPE_NORMAL
- en: Piuri
  prefs: []
  type: TYPE_NORMAL
- en: G
  prefs: []
  type: TYPE_NORMAL
- en: ', Zocchi'
  prefs: []
  type: TYPE_NORMAL
- en: M , Della Porta
  prefs: []
  type: TYPE_NORMAL
- en: M , et al.
  prefs: []
  type: TYPE_NORMAL
- en: Magnesium in obesity, metabolic syndrome, and type 2 diabetes
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Nutrients
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2021'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '13'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '2'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '320'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '20'
  prefs: []
  type: TYPE_NORMAL
- en: Pelczyńska
  prefs: []
  type: TYPE_NORMAL
- en: M
  prefs: []
  type: TYPE_NORMAL
- en: ', Moszak'
  prefs: []
  type: TYPE_NORMAL
- en: M , Bogdański
  prefs: []
  type: TYPE_NORMAL
- en: P .
  prefs: []
  type: TYPE_NORMAL
- en: The role of magnesium in the pathogenesis of metabolic disorders
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Nutrients
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2022'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '14'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '9'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '1714'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '21'
  prefs: []
  type: TYPE_NORMAL
- en: Rodríguez-Morán
  prefs: []
  type: TYPE_NORMAL
- en: M
  prefs: []
  type: TYPE_NORMAL
- en: ', Simental-Mendía'
  prefs: []
  type: TYPE_NORMAL
- en: LE , Gamboa-Gómez
  prefs: []
  type: TYPE_NORMAL
- en: CI , Guerrero-Romero
  prefs: []
  type: TYPE_NORMAL
- en: F .
  prefs: []
  type: TYPE_NORMAL
- en: 'Oral magnesium supplementation and metabolic syndrome: a randomized double-blind
    placebo-controlled clinical trial'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Adv Chronic Kidney Dis
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2018'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '25'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '3'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '261'
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: '266'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '22'
  prefs: []
  type: TYPE_NORMAL
- en: Ismail
  prefs: []
  type: TYPE_NORMAL
- en: Y
  prefs: []
  type: TYPE_NORMAL
- en: ', Ismail'
  prefs: []
  type: TYPE_NORMAL
- en: AA , Ismail
  prefs: []
  type: TYPE_NORMAL
- en: AAA .
  prefs: []
  type: TYPE_NORMAL
- en: The underestimated problem of using serum magnesium measurements to exclude
    magnesium deficiency in adults; a health warning is needed for “normal” results
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Clin Chem Lab Med
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2010'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '48'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '3'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '323'
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: '327'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '23'
  prefs: []
  type: TYPE_NORMAL
- en: Ismail
  prefs: []
  type: TYPE_NORMAL
- en: A
  prefs: []
  type: TYPE_NORMAL
- en: ', Ismail'
  prefs: []
  type: TYPE_NORMAL
- en: Y , Ismail
  prefs: []
  type: TYPE_NORMAL
- en: AA .
  prefs: []
  type: TYPE_NORMAL
- en: Chronic magnesium deficiency and human disease; time for reappraisal
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: QJM
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2018'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '111'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '11'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '759'
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: '763'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '24'
  prefs: []
  type: TYPE_NORMAL
- en: Elin
  prefs: []
  type: TYPE_NORMAL
- en: RJ
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: 'Magnesium: the fifth but forgotten electrolyte'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Am J Clin Pathol
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '1994'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '102'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '5'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '616'
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: '622'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '25'
  prefs: []
  type: TYPE_NORMAL
- en: Elisaf
  prefs: []
  type: TYPE_NORMAL
- en: M
  prefs: []
  type: TYPE_NORMAL
- en: ', Panteli'
  prefs: []
  type: TYPE_NORMAL
- en: K , Theodorou
  prefs: []
  type: TYPE_NORMAL
- en: J , Siamopoulos
  prefs: []
  type: TYPE_NORMAL
- en: KC .
  prefs: []
  type: TYPE_NORMAL
- en: Fractional excretion of magnesium in normal subjects and in patients with hypomagnesemia
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Magnes Res
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '1997'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '10'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '4'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '315'
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: '320'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '26'
  prefs: []
  type: TYPE_NORMAL
- en: Zhang
  prefs: []
  type: TYPE_NORMAL
- en: X
  prefs: []
  type: TYPE_NORMAL
- en: ', Del Gobbo'
  prefs: []
  type: TYPE_NORMAL
- en: LC , Hruby
  prefs: []
  type: TYPE_NORMAL
- en: A , et al.
  prefs: []
  type: TYPE_NORMAL
- en: The circulating concentration and 24-h urine excretion of magnesium dose- and
    time-dependently respond to oral magnesium supplementation in a meta-analysis
    of randomized controlled trials
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: J Nutr
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2016'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '146'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '3'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '595'
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: '602'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '27'
  prefs: []
  type: TYPE_NORMAL
- en: Ryzen
  prefs: []
  type: TYPE_NORMAL
- en: E
  prefs: []
  type: TYPE_NORMAL
- en: ', Elbaum'
  prefs: []
  type: TYPE_NORMAL
- en: N , Singer
  prefs: []
  type: TYPE_NORMAL
- en: FR , Rude
  prefs: []
  type: TYPE_NORMAL
- en: RK .
  prefs: []
  type: TYPE_NORMAL
- en: Parenteral magnesium tolerance testing in the evaluation of magnesium deficiency
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Magnesium
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '1985'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '4'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: 2–3
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '137'
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: '147'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '28'
  prefs: []
  type: TYPE_NORMAL
- en: Arnaud
  prefs: []
  type: TYPE_NORMAL
- en: MJ
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Update on the assessment of magnesium status
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Br J Nutr
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2008'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '99'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: Suppl 3
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: S24
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: S36
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '29'
  prefs: []
  type: TYPE_NORMAL
- en: Rubenowitz
  prefs: []
  type: TYPE_NORMAL
- en: E
  prefs: []
  type: TYPE_NORMAL
- en: ', Axelsson'
  prefs: []
  type: TYPE_NORMAL
- en: G , Rylander
  prefs: []
  type: TYPE_NORMAL
- en: R .
  prefs: []
  type: TYPE_NORMAL
- en: Magnesium in drinking water and body magnesium status measured using an oral
    loading test
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Scand J Clin Lab Invest
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '1998'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '58'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '5'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '423'
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: '428'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '30'
  prefs: []
  type: TYPE_NORMAL
- en: Rylander
  prefs: []
  type: TYPE_NORMAL
- en: R
  prefs: []
  type: TYPE_NORMAL
- en: ', Mégevand'
  prefs: []
  type: TYPE_NORMAL
- en: Y , Lasserre
  prefs: []
  type: TYPE_NORMAL
- en: B , Amstutz
  prefs: []
  type: TYPE_NORMAL
- en: W , Granbom
  prefs: []
  type: TYPE_NORMAL
- en: S .
  prefs: []
  type: TYPE_NORMAL
- en: Moderate alcohol consumption and urinary excretion of magnesium and calcium
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Scand J Clin Lab Invest
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2001'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '61'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '5'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '401'
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: '405'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '31'
  prefs: []
  type: TYPE_NORMAL
- en: Gröber
  prefs: []
  type: TYPE_NORMAL
- en: U
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Magnesium and drugs
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Int J Mol Sci
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2019'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '20'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '9'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '2094'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '32'
  prefs: []
  type: TYPE_NORMAL
- en: William
  prefs: []
  type: TYPE_NORMAL
- en: JH
  prefs: []
  type: TYPE_NORMAL
- en: ', Danziger'
  prefs: []
  type: TYPE_NORMAL
- en: J .
  prefs: []
  type: TYPE_NORMAL
- en: 'Proton-pump inhibitor-induced hypomagnesemia: current research and proposed
    mechanisms'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: World J Nephrol
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2016'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '5'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '2'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '152'
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: '157'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '33'
  prefs: []
  type: TYPE_NORMAL
- en: de Baaij
  prefs: []
  type: TYPE_NORMAL
- en: JH
  prefs: []
  type: TYPE_NORMAL
- en: ', Hoenderop'
  prefs: []
  type: TYPE_NORMAL
- en: JG , Bindels
  prefs: []
  type: TYPE_NORMAL
- en: RJ .
  prefs: []
  type: TYPE_NORMAL
- en: 'Magnesium in man: implications for health and disease'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Physiol Rev
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2015'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '95'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '1'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '1'
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: '46'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '34'
  prefs: []
  type: TYPE_NORMAL
- en: Sarrafzadegan
  prefs: []
  type: TYPE_NORMAL
- en: N
  prefs: []
  type: TYPE_NORMAL
- en: ', Khosravi-Boroujeni'
  prefs: []
  type: TYPE_NORMAL
- en: H , Lotfizadeh
  prefs: []
  type: TYPE_NORMAL
- en: M , Pourmogaddas
  prefs: []
  type: TYPE_NORMAL
- en: A , Salehi-Abargouei
  prefs: []
  type: TYPE_NORMAL
- en: A .
  prefs: []
  type: TYPE_NORMAL
- en: 'Magnesium status and the metabolic syndrome: a systematic review and meta-analysis'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Nutrition
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2016'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '32'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '4'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '409'
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: '417'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '35'
  prefs: []
  type: TYPE_NORMAL
- en: Song
  prefs: []
  type: TYPE_NORMAL
- en: Y
  prefs: []
  type: TYPE_NORMAL
- en: ', Li'
  prefs: []
  type: TYPE_NORMAL
- en: TY , van Dam
  prefs: []
  type: TYPE_NORMAL
- en: RM , Manson
  prefs: []
  type: TYPE_NORMAL
- en: JE , Hu
  prefs: []
  type: TYPE_NORMAL
- en: FB .
  prefs: []
  type: TYPE_NORMAL
- en: Magnesium intake and plasma concentrations of markers of systemic inflammation
    and endothelial dysfunction in women
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Am J Clin Nutr
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2007'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '85'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '4'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '1068'
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: '1074'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '36'
  prefs: []
  type: TYPE_NORMAL
- en: Han
  prefs: []
  type: TYPE_NORMAL
- en: H
  prefs: []
  type: TYPE_NORMAL
- en: ', Fang'
  prefs: []
  type: TYPE_NORMAL
- en: X , Wei
  prefs: []
  type: TYPE_NORMAL
- en: X , et al.
  prefs: []
  type: TYPE_NORMAL
- en: 'Dose-response relationship between dietary magnesium intake, serum magnesium
    concentration and risk of hypertension: a systematic review and meta-analysis
    of prospective cohort studies'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Nutr J
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2017'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '16'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '1'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '26'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '37'
  prefs: []
  type: TYPE_NORMAL
- en: Găman
  prefs: []
  type: TYPE_NORMAL
- en: M-A
  prefs: []
  type: TYPE_NORMAL
- en: ', Dobrică'
  prefs: []
  type: TYPE_NORMAL
- en: E-C , Cozma
  prefs: []
  type: TYPE_NORMAL
- en: M-A , et al.
  prefs: []
  type: TYPE_NORMAL
- en: 'Crosstalk of magnesium and serum lipids in dyslipidemia and associated disorders:
    a systematic review'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Nutrients
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2021'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '13'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '5'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '1411'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '38'
  prefs: []
  type: TYPE_NORMAL
- en: Nik
  prefs: []
  type: TYPE_NORMAL
- en: WNFHW
  prefs: []
  type: TYPE_NORMAL
- en: ', Zulkeflee'
  prefs: []
  type: TYPE_NORMAL
- en: HA , Ab Rahim
  prefs: []
  type: TYPE_NORMAL
- en: SN , Tuan Ismail
  prefs: []
  type: TYPE_NORMAL
- en: TST .
  prefs: []
  type: TYPE_NORMAL
- en: Association of vitamin D and magnesium with insulin sensitivity and their influence
    on glycemic control
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: World J Diabetes
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2023'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '14'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '1'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '26'
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: '34'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '39'
  prefs: []
  type: TYPE_NORMAL
- en: ELDerawi
  prefs: []
  type: TYPE_NORMAL
- en: WA
  prefs: []
  type: TYPE_NORMAL
- en: ', Naser'
  prefs: []
  type: TYPE_NORMAL
- en: IA , Taleb
  prefs: []
  type: TYPE_NORMAL
- en: MH , Abutair
  prefs: []
  type: TYPE_NORMAL
- en: AS .
  prefs: []
  type: TYPE_NORMAL
- en: The effects of oral magnesium supplementation on glycemic response among type
    2 diabetes patients
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Nutrients
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2018'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '11'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '1'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '44'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '40'
  prefs: []
  type: TYPE_NORMAL
- en: Ghasemi
  prefs: []
  type: TYPE_NORMAL
- en: A
  prefs: []
  type: TYPE_NORMAL
- en: ', Zahediasl'
  prefs: []
  type: TYPE_NORMAL
- en: S , Syedmoradi
  prefs: []
  type: TYPE_NORMAL
- en: L , Azizi
  prefs: []
  type: TYPE_NORMAL
- en: F .
  prefs: []
  type: TYPE_NORMAL
- en: Low serum magnesium levels in elderly subjects with metabolic syndrome
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Biol Trace Elem Res
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2010'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '136'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '1'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '18'
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: '25'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '41'
  prefs: []
  type: TYPE_NORMAL
- en: Simmons
  prefs: []
  type: TYPE_NORMAL
- en: D
  prefs: []
  type: TYPE_NORMAL
- en: ', Joshi'
  prefs: []
  type: TYPE_NORMAL
- en: S , Shaw
  prefs: []
  type: TYPE_NORMAL
- en: J .
  prefs: []
  type: TYPE_NORMAL
- en: 'Hypomagnesaemia is associated with diabetes: not pre-diabetes, obesity or the
    metabolic syndrome'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Diabetes Res Clin Pract
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2010'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '87'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '2'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '261'
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: '266'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '42'
  prefs: []
  type: TYPE_NORMAL
- en: Yu
  prefs: []
  type: TYPE_NORMAL
- en: Y
  prefs: []
  type: TYPE_NORMAL
- en: ', Cai'
  prefs: []
  type: TYPE_NORMAL
- en: Z , Zheng
  prefs: []
  type: TYPE_NORMAL
- en: J , et al.
  prefs: []
  type: TYPE_NORMAL
- en: Serum levels of polyunsaturated fatty acids are low in Chinese men with metabolic
    syndrome, whereas serum levels of saturated fatty acids, zinc, and magnesium are
    high
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Nutr Res
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: '2012'
  prefs: []
  type: TYPE_NORMAL
- en: ;
  prefs: []
  type: TYPE_NORMAL
- en: '32'
  prefs: []
  type: TYPE_NORMAL
- en: (
  prefs: []
  type: TYPE_NORMAL
- en: '2'
  prefs: []
  type: TYPE_NORMAL
- en: '):'
  prefs: []
  type: TYPE_NORMAL
- en: '71'
  prefs: []
  type: TYPE_NORMAL
- en: ‐
  prefs: []
  type: TYPE_NORMAL
- en: '77'
  prefs: []
  type: TYPE_NORMAL
- en: .
  prefs: []
  type: TYPE_NORMAL
- en: Abbreviations
  prefs:
  - PREF_H2
  type: TYPE_NORMAL
- en: ALT
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
- en: AST
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
- en: BMI
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
- en: Ca
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
- en: DBP
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
- en: eGFR
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
- en: estimated glomerular filtration rate
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
- en: FEMg
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
- en: fractional excretion of magnesium
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
- en: HbA[1c]
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
- en: HDL-C
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
- en: high-density lipoprotein cholesterol
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
- en: HOMA-IR
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
- en: homeostatic model assessment for insulin resistance
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
- en: LDL-c
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
- en: low-density lipoprotein cholesterol
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
- en: MDS
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
- en: magnesium depletion score
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
- en: MetS
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
- en: NCEP-ATP III
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
- en: National Cholesterol Education Program Adult Treatment Panel III Criteria
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
- en: NHANES
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
- en: National Health and Nutrition Examination Survey
  prefs:
  - PREF_IND
  type: TYPE_NORMAL
- en: OR
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
- en: PPI
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
- en: RCS
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
- en: SBP
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
- en: TC
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
- en: TGs
  prefs:
  - PREF_UL
  type: TYPE_NORMAL
- en: © The Author(s) 2024\. Published by Oxford University Press on behalf of the
    Endocrine Society.
  prefs: []
  type: TYPE_NORMAL
- en: This is an Open Access article distributed under the terms of the Creative Commons
    Attribution License (
  prefs: []
  type: TYPE_NORMAL
- en: '[https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)'
  prefs: []
  type: TYPE_NORMAL
- en: ), which permits unrestricted reuse, distribution, and reproduction in any medium,
    provided the original work is properly cited.
  prefs: []
  type: TYPE_NORMAL
